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Ace   Adhesion to collagen from E. faecalis 
AP1    Activator protein 1 
AP2   Activator protein 2 
AS   Aggregation substance 
ATG   Start codon 
attX   Attachment site X, were x denotes L, R, 1 or 2 
Bp   Base pairs 
CACC   Overhang in cloning 
CC17   Clonal complex 17 
Cfu   Colony forming unit 
CWSS   Cell wall sorting signal 
CWAPs  Cell wall anchored proteins 
ddNTP   dideoxynucleotide triphosphate 
df   degree of freedom, a statically term 
DMSO   dimethyl sulfoxide 
dNDT   deoxynucleotide diphosphate 
dNMP   deoxynucleotide monophosphate 
dNTP   deoxynucleotide triphosphate 
dsDNA  Double stranded DNA 
DNA   Deoxyribonucleic acid 
E   In χ2: Expected number 
Ebp   Endocarditis and biofilm-associated pili 
ECM   Extra cellular matrix  
Esp   Enterococci surface protein   
EtBr   Etidium Bromide 
EXO   Exonuclease 
G   Glycine in peptides 
   Gravity in centrifugation 
G/C   Guanine/cytosine content 
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GI   Gastrointestinal tract 
His   Histidine 
IgX   Immunoglobulin, x denotes M, D, A, G or E 
kDa   Kilo Dalton 
LB   Luria-Bertani media 
LPXTG  Leucine- Proline- any amino acid- Threonine- Glycine  
µg   Micro gram 
µl   Micro litre 
MRSA   Meticillin resistant Staphylococcus aureus 
MSCRAMMs  Microbial surface cell recognition adhesion matrix molecules 
N   In DNA sequence: Any nucleotide 
NaCl   Sodium Chloride 
NaOH   Sodium Hydroxide 
ng   Nano gram  
Ni   Nickel 
O   In χ2: Observed number 
OD   Optic density 
PBP   Penicillin binding protein 
PCR   Polymerase Chain Reaction 
PFGE   Pulsfield gel electrophoresis 
PGC   Pili gene cluster 
RBS   Ribosome binding site 
RNase   Ribonuclease 
rpm   Rotations pr minute 
SAP   Shrimp Alkaline Phosphatase 
SDS-PAGE  Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
ssDNA  Single stranded DNA 
T   Threonine in peptides 
TBE   Tris/Borate/EDTA 
TBS   Tris buffered saline 
TBST   TBS with triton 
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TE   Tris EDTA 
UV   Ultra violet 
V   Volt 
VBNC   Viable but not culturable 
VRE   Vancomycin resistant enterococci 
VREfm  Vancomycin resistant Enterococcus faecium 





Enterococci were first described as a group in 1984 when it was discovered that 
Streptococcus faecium and Streptococcus faecalis did not belong to the streptococci. 
Today over 20 species of enterococci are described [Franz et al. 1999, Klein 2003). The 
enterococci are gram-positive, facultative anaerobic, lactic acid bacteria. They are 
catalase negative, and belong to the low G/C content of the genra Firmicutes. The normal 
habitat for enterococci is the gastro intestinal tract (GI) of mammals and humans, and soil 
[Franz et al. 1999, Foulquie Moreno et al. 2006]. The enterococci occur as single cells, in 
pairs or as short chains, the optimum growth temperature is 35˚C, but they can grow at 
temperatures between 10˚C and 45˚C. Enterococci can even survive at 60˚C for 30 
minutes [Franz et al. 1999, Foulquie-Moreno et al. 2006, Top et al. 2008]. They grow in 
broth containing 6,5% NaCl, and hydrolyse esculin in the presence of 40% bile salts 
[Foulquie Moreno et al. 2006]. The enterococci are also able to survive extreme 
temperature and chemical disfectants like chlorine, glutaraldehyde and alcohol [Kearns et 
al. 1995, Bradley & Fraise 1996]. In addition to these harsh conditions enterococci can 
survive in environments with little nutrients by entering a viable but non-culturable 
(VBNC) state, where the cells are metabolically active and can resume a normal state 
when the environment are back to normal  [Fischetti et al 2006], an example of such an 
environment are the treated root canals in teeth which are treated with harsh chemicals 
and are a poor nutritional environment [Pinheiro et al. 2003], and tap water were the 
enterococci are exposed to a environment which is low on nutrients and thereby causes 
nutritional stress on the cells [Byrd et al. 1991, Hartke et al.1998]. 
 
28 enterococci species are known [Foulquie-Moreno et al. 2006]. There has been an 
attempt of dividing these species into enterococci species groups based on 16S rRNA 
data [Franz et al. 1999, Klein 2003, Foulquie-Moreno]. In 2003 Günter Klein divided the 
then 22 described species into 7 different groups: 
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1) E. faecalis group: E. faecalis, E. haemoperoxidus and E. moravinensis. 
2) E. faecium group: E. faecium, E. durans, E. hirae, E. mundtii, E. porcinus and E. 
villorum. 
3) E. avium group: E. avium, E. pseudoavium, E. maoldoratus and E. raffinosus. 
4) E. casseliflavus group: E. casseliflavus, E. gallinarum and E. flavescens. 
5) E. cecrum group: E. cecrum and E. columbae. 
6) E. dispar group: E. dispar and E. asini. 
7) E. saccharolyticus group: E. saccharolyticus and E. sulfureus. 
 
According to molecular data E. solitarius belongs to the Tetragenococci [Klein 2003], E. 
solitarius is mentioned as enterococci in 2006 by the Foulquie-Morenos group [Foulquie-
Moreno et al. 2006]. Other enterococci species that does not belong to any group: E. 
gilvus, E. pallens, E. ratti [Klein 2003, Foulquie-Moreno et al. 2006], E. canis, E. 
phoenoculicola and E. saccharominimus [Foulquie-Moreno 2006]. E. faecium and E. 
faecalis are the enterococci that are most often associated with infections in humans. 
 
Enterococci are opportunistic bacteria, and when found in niches they do not normally 
live in, such as in the urinary tract, heart giardi cells, vagina, blood and mouth, they can 
cause serious infections like bacteraemia, endocarditis and urinary tract infections 
[Donelli et al. 2004]. There are two ways enterococci can cause infections. In one way 
infections are caused by the enterococci that originate from the patients native flora, these 
enterococci are unlikely to possess acquired antibiotic resistance, but possess intrinsic 
resistance that is normal for the species. The other type of infections is caused by bacteria 
that often possess acquired resistance to antibiotics, in addition to the intrinsic, and is 
capable of nosocomial transmission. Spread of enterococci between patients probably 
goes via hands of health-care providers and medical devices, while spread between 
hospitals is caused by patients with prolonged intestinal colonization [Huycke et al. 1998] 
 
Clinical infections can involve almost any anatomic site, and may be life-threatening 
during bacteriemia and endocarditis, the features of infections are variable [Murray 1990, 
Lu et al. 2002]. Resistance to vancomycin in enterococci more than doubles the odds for 
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dying during bloodstream infections by VRE [DiazGrandos et al. 2005]. In one large 
study, enterococci were the only Gram-positive pathogen independently associated with 
high risk of death in bloodstream infections [Weinstein et al 1983].  Enterococcal 
bacteriemia leads to death in 12%-68% of the cases, with death due to enterococcal sepsis 
in 4%-50% of these cases [Jett et al. 1994]. 
 
Use of Enterococci 
Enterococci are usually considered heavy fermentors due to their lack of Krebs cycle and 
respirator chain [Huycke et al 1998], and because of this enterococci have been used as 
fermentors in the food industry. 
 
Enterococci are present in many sorts of food, especially food that origin from animals, 
due to the presence of enterococci in the GI of animals. Historically isolation of E. 
faecium and E. faecalis from food has been an indication of faecal contamination in the 
production line of the food [Klein 2003]. Today enterococci are considered a natural part 
of the normal microbial flora of food [Klein 2003].  
 
Because of their ability to produce bacteriocins, and their organoleptic1 properties, 
enterococci are used in the food industry as e.g. in the cheese industry were they might 
contribute to the ripening and aroma of the cheese [Foulquié Moreno et al. 2006]. The 
levels of enterococci in cheese curds lies between 104 and 106 colony forming units 
(cfu)/g, while in the ripened cheese the cfu/g is between 105 to 107, E. faecium and E. 
faecalis are the dominant species [Foulquié Moreno et al. 2006]. In some cheeses, like 
Mozzarella, the enterococci are the predominant microorganism used [Foulquié Moreno 
et al. 2006].  
 
The levels of enterococci varies from cheese to cheese as a result from the production 
season, the extent of contamination of the milk and water used, the survival in the dairy 
                                                 
1 Sensory properties of a product including: taste, color, smell and consistency/ how it feels. Organoleptic 
testing is done by visually inspection, feeling and smelling the product. 
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environment, and survival and growth under the particular conditions of the cheese 
production and ripening [Foulquié-Moreno et al. 2006]. 
 
When a bacterial strain is to be used as a probiotic, live microbial feed supplements that 
benefit and improve the host intestinal microbial balance, they have to be able to adhere 
to cells and exclude or reduce the adherence of pathogenic adherence, they have to persist 
and multiply, and produce acids, hydrogen peroxide and bacteriocins antagonistic2 to 
pathogen growth. The strains have to be safe, in the meaning of being non-invasive, non-
carcinogenic and non-pathogenic, and it has to contribute to the formation of a balanced 
normal flora [Salminen et al. 1996]. Both E. faecalis and E. faecium have been used as 
probiotics. E. faecium SF68 has been clinically effective in the prevention of antibiotic 
associated diarrhea in children, and has made the duration of diarrhea in adults, it has also 
been used as feed probiotic, in dry dog food, and in milk in Denmark [Foulquié-Moreno 
et al. 2006], which shows the broad use of probiotics in society. 
 
The uses of enterococci as probiotics are controversial. While some strains benefit the 
host, the emergence of antibiotic resistant strains, and the increase infections in humans 
caused by antibiotic resistant enterococci, especially VRE, has lead to concern regarding 
the use of enterococci as probiotic [Folquié-Moreno et al. 2006]. 
 
Virulence of Enterococci 
Enterococci have failed to cause chronic or sever infections after inoculation into 
subcutaneous tissue or peritoneal cavity in laboratory animals, which has been used as the 
main argument of enterococci being non-pathogen organisms [Jett et al. 1994], despite 
this the enterococci have emerged as a major nosocomial pathogen over the last decades. 
 
Known and putative virulence factors in enterococci are: Cytolysin, pheromones, 
aggregation substance (AS), protease, lipoteiochoic acid, hylauronidase, AS 48, 
hemolysin, gelatinase [Jett et al. 1994], enterococci surface proteins (esp), adhesion to 
                                                 
2 Chemical substance that interfere with the physiological action of another chemical 
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collagen from E. faecalis (Ace) (Budzik & Schneewind 2006), biofilm production, ebp 
[Singh et al. 2006], MSCRAMMs [Sillanpää et al. 2004], resistance to phagocytosis by 
neutrophils [Arduino et al. 1994, Rakita et al. 1999], secreted antigens SagA [Teng et al. 
2003] and Acm [Nallapareddy et al. 2003], quorum sensing [Nakayama et al 2001], and 
production of hydrogen peroxide [Moy et al. 2004]. 
 
In addition enterococci are known to transfer mobile genetic elements that often contain 
genes for antibiotic resistance and/or other virulence factors to other enterococci species, 
Gram-positive and Gram-negative species [Donelli 2004]. Antibiotic resistance is 
considered as an important pathogenicity property of enterococci [Foulquié Moreno et al. 
2006]. 
 
Antibiotic Resistance  
Antibiotic resistance is often caused by antibiotic pressure in the environment of the 
bacteria, and the occurrence of antibiotic resistance is more frequent in hospital 
environment than in the community. A study from Germany showed that antibiotic 
resistant E. faecalis in the community was highly associated with recent intake of 
antibiotics, but resistance to quinolones in E. faecium was more common and not 
associated with recent use of the antibiotic [Lietzau et al. 2006] 
 
Main mechanisms for antibiotic resistance are inactivation of the drug, prevention of the 
drug to reach its target site, reduction of the target susceptibility, and acquisition of a new 
less sensitive target [Berger-Bächi 2002]. Enterococci harbour both intrinsic and acquired 
drug resistance. A new drug, tigecycline, with anti-enterococci activity can be used to 
treat infections caused by enterococci [Pankey 2005]. 
 
Intrinsic drug resistance is due to mechanisms that are natural for the organism, and the 
drugs enterococci have intrinsic resistance to vary among the species. Enterococci can 
harbour intrinsic resistance against new drugs like E. faecalis resistance to quinopristin-
dalfopristin, community reservoir in US and Europe have emerged due to the widespread 
use of the analogue virginiamycin as growth promoter [Acar et al. 2000].  
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Acquired drug resistance is often due to mutations, and exchange or acquisition of 
genetic mobile elements such as transposones and plasmids. The genetic mobile elements 
often contains the genes for other virulence factors instead of resistance to antibiotics, or 
in addition to, and enterococci can transfer these elements to both Gram negative and 
Gram positive bacteria, which make them even more potent. E. faecium, E. hirae and E. 
faecalis are known to acquire high level resistance to ampicillin by overproduction of 
PBP5 or in some cases production of β-lactamase [Top et al. 2008]. 
 
Biofilm 
Enterococci are known to produce slime, an amorphous extracellular substance made of 
polysaccharides, and is one of the major components of bacterial biofilm [Donelli et al. 
2004], which is the term used about microbial colonies encased in adhesive material, i.e. 
polysaccharide, attached to a surface [Madigan et al. 2003]. Biofilm protects the 
microorganisms from host defence and some antimicrobial drugs [Merode et al. 2006] 
and is an important factor in the attachment of enterococci to surfaces and other cells; it is 
one of the virulence factors in many pathogenic enterococci strains [Hufnagel et al. 
2004]. The composition of the growth media has an influence on the production of 
biofilm by the enterococci, the presence of additional carbohydrates or de depletion of 
iron favour the biofilm production [Baldassarri et al 2001]. Other factors that favour the 
production of biofilm are the transcriptional regulator BopD [Hufnagel et al. 2004], the 
gene products of the quorum sensing locus fsr and gelatinase (GelE) [Hancock & Perego 
2004] and ebp [Singh et al 2006]. 
 
In clinical strains of E. faecium slime production is more frequent than in environmental 
strains and isolates from healthy individuals, and because of this biofilm is thought to be 
one of the virulence factors of enterococci [Donelli et al. 2004]. Compared to 




”Aggregation substance” (AS) is regarded as one of the main virulence factors in 
enterococci [IsenMann et al. 2002], and is described in both E. faecalis and E. faecium 
[Donelli et al. 2004]. AS is a plasmid encoded surface protein that is expressed as a 
response to specific pheromones, and this lead to the promotion the formation of  mating 
pair and conjugative transfer via the sex pheromone system [Donelli et al 2004]. 
 
Enterococci expressing AS are frequently found among clinical isolates, and expression 
of AS promotes enterococci adhesion to cultured human cells, this is either directly or 
indirectly by increasing the number of organisms taken up as a clump [Donelli et al. 
2004, IsenMann et al. 2002], and it significantly enhance E. faecalis adherence to 
immobilized ECM [IsenMann et al. 2002]. Expression of AS also promotes the invasion 
of enterococci into different cell types, including macrophages [IsenMann et al. 2002]. 
 
Cell Wall Associated Proteins 
Cell wall anchored proteins (CWAPs) exposed on the surface are used by bacterial 
pathogens to interact with other cells, and potentially mount a successful infection of the 
host [Dramsi et al. 2008]. Cell wall sorting signals (CWSS) is needed for an efficient 
sorting to the cell wall; the CWSS are N-terminus leader peptides. CWSS in Gram-
positive bacteria are generally longer, more hydrophobic and more charged at their N-
terminus than their counterparts in Gram-negative bacteria [Dramsi et al. 2008]. The C-
terminus of the CWAPs consists of an LPXTG motif, and hydrophobic domain and a 
positively charged tail; these characteristics are also needed for an efficient sorting to the 
cell wall [Dramsi et al. 2008]. The LPXTG motif of CWAPs are typically considered 
LPXTG sortase substrate, after the translocation over the plasma membrane CWAPs are 
anchored to the cell wall by a the transpeptidase activity in the sortases [Hendrickx et al. 
2007]. 
 
Proteins exposed on the cell surface are frequently considered as potential virulence 
factors [Desvaux et al. 2006], esp and acm are examples of CWAPs found in E. faecium 
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and associated with the formation of biofilm and better adherence to ECM resulting in a 




Together with Enterococcus faecalis, Enterococcus faecium is the most common 
enterococci in clinical isolates from human infections. While the numbers of infections 
caused by E. faecalis and other human pathogen enterococci are stable, the infection rate 
of E. faecium is increasing [Iwen et al. 1997, Top et al. 2007].  
 
E. faecium is often responsible for urinary tract infections, surgical site infections, 
bacteriemia and endocarditis. E. faecium is the enterococci most often associated with 
increasing resistance to different classes of antibiotics such as penicillins, 
aminoglycosides and glycopeptides [Hendrickx et al. 2007]. 
  
Geographic Distribution   
Ampicillin resistance in enterococci is due to penicillin binding proteins (PBP) with low 
affinity for β-lactam, high level of resistance is often associated with E. faecium. In the 
US the first reports of infections caused by ampicillin resistant E. faecium was reported in 
the early 1980s. The same was the case for Europe- 10 years later [Top et al. 2007].  
 
In 1986 the first cases of glycopetide resistant enterococci were reported in Europe, and it 
spread all over the world. Infection caused by vancomycin resistant enterococci (VRE) in 
the US increased from 0% in 1989 to 28,5% in 2003, and in the 1990s VRE had become 
the second most common nosocomial pathogen, and were endemic in many hospitals 
around the US.  [Top 2007] 
 
The differences of occurrence of enterococci the US and Europe are severe. In the US 
colonization of VRE in hospitalised patients increased rapidly in the 1990s to reach the 
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present levels. In Europe the prevalence rates in hospitals remained much lower until 
2000, when it started to increase. The suggested reason for this is the much higher use of 
vancomycin in US hospitals than in European hospitals, a comparison made between US 
and European countries with similar numbers of inhabitants [Top 2007] 
 
In Europe there is a large reservoir of VRE in healthy people and animals in the 
community. This is not the case for the US. The reason for this is the massive use of 
avoparcin, a glycopetide with the same function as vancomycin, as a growth promoter in 
animal husbandry in most European countries since the 1970s. After the ban of avoparcin 
use in the food industry the number of healthy animal and humans with VRE decreased.  
In the US vancomycin has been strictly restricted to hospitals, and was not used in the 
agricultural industry, and the reservoir in healthy humans and animals have therefore not 
been a problem in the US [Top 2007]. 
 
Population Structure  
Isolates from humans, pigs and poultry have shown specific genetic lineages, poultry and 
pigs tend to cluster in distinctive branches [Willems et al. 2000, Leavis et al. 2006]. 
Vancomycin resistant E. faecium from human volunteers cluster together with pig 
isolates, while vancomycin resistant E. faecium from documented nosocomial outbreaks 
and infections clustered in another distinct branch, showing the existence of host specific 
lineages and distinct genetic a distinct genetic subpopulation of enterococci representing 
clinical and hospital outbreak isolates [Willems et al. 2000, Leavis et al. 2006]. Figure 1 
shows the distinct branch made up of the clinical isolates. 
 15
 
Figure 1- The figure shows the population structure of enterococci. [Leavis et al. 2006] 
 
Clonal Complex 17 
Successful clonal complexes have adapted to the environment through a series of 
mutations and acquisition of genetic elements giving the bacteria a selective advantage in 
the selective pressure it is exposed to. Such acquired properties can be resistance to 
antibiotics, increased virulence e.g. due to new MSCRAMMs, increased production of 
biofilm and increased ability to use alternative metabolic pathways [Hendrickx et al. 
2007, Leavis et al. 2007, Top et al. 2007]. 
 
Many clinical E. faecium isolates contains clonal complex 17, these E. faecium are called 
E. faecium CC17 isolates, or just CC17 isolates. There are two key features of CC17 
isolates; the first is high resistance to antibiotics like ampicillins and ciprofloxacins. The 
other key feature is the presence of putative pathogenicity islands harboring the esp and 
acm genes and probably the hylEfm [Hendrickx et al. 2007]. These features of CC17 
isolates suggest that they might be more virulent than non-CC17 isolates, and contribute 
to selective advantage in hospital settings [Hendrickx et al. 2007]. Other features 
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associated with CC17 are ampicillin resistance and higher levels of quinolone resistance, 
which is also the characteristic of globally spread CC17 [Leavis et al. 2006].  
 
The adaptation of CC17 to hospitals is probably a multistep process involving the 
sequential acquisition of adaptive mechanisms that gives E. faecium CC17 a selective 
advantage over non-CC17 E. faecium, and thus leading to the acquisitions of more 
selective advantages, eventually leading to a specialized genetic subpopulation that have 
a greater chance of surviving and spreading in the hospital environment [Leavis et al. 
2006, Hendrickx et al. 2007]. 
 
It has been suggested that E. faecium may enter the community during the food chain [Lu 
et al. 2001], humans and animals in close contact seem to harbor identical strains of E. 
faecium. Transfer between poultry and pigs seem to be less common, but both poultry 
and pigs can be the strain source of E. faecium in humans. Primary transmission is 
suggested to be from animal to human, not human to animal. [Lu et al. 2001]. A study 
performed in China after an outbreak of E. faecium-related sepsis in both humans and 
pigs in 1998 were 12 out of 40 infected humans died [Lu et al. 2001]. The PFGE patterns 
of the isolates obtained from both humans and pigs indicated that the isolates were clonal 
[Lu et al. 2001].  
 
Pili 
Pili in Gram-positive bacteria were first described by Yanagawa in 1968 in 
Croynebacteria, and a while later in streptococci that inhabits the oral cavity [Scott and 
Zähner 2006]. Pili-like structures have been indentified in electron microscopy in 
Croynebacteria, streptococci, enterococci and pneumococci and has been characterized 
both genetically and biochemically [Ton-That & Schneewind 2003, Lauer et al. 2005]. 
The structures have been found to be extended polymers formed by a transpeptidase 
reaction performed by a specific sortase that cross-link the LPXTG motifs in the subunits. 
The sortases have also been found to be responsible for the covalent attachment to the 
peptidoglycan in the cell wall [Barocchi et al. 2006]. The typical heterodimeric pili are 
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composed of one major subunit that forms the backbone of the pili structure, one minor 
subunit and a subunit forming the tip of the pili [Hendrickx et al. 2008]. 
 
One model for pili in Gram positives is the pneumococcal pili. The genes encoding the 
pili subunits and its sortases are found to be in an rlrA islet containing seven genes 
[Barocchi et al. 2006]. Three of these genes, rgrA, rgrB and rgrC, are thought to encode 
LPXTG containing microbial surface components recognizing adhesive matrix 
molecules, so called MSCRAMMs that bind to components of the ECM of the host. RgrB 
is thought to be the main pili subunit; this is based on the result of antibody labelling to 
the pili structure. Antibodies for rgrB protein labelled the whole pili structure, whereas 
antibodies for rgrA protein labelled the cell surface indicating that this protein associates 
the pili structure to the surface, and antibodies for the rgrC protein decorated the tip of 
the structure [Barocchi et al. 2006].  
  
Three other genes, srtB, srtC and srtD, are predicted to encode sortases [Barocchi et al. 
2006]. A transcriptional repressor, mgrA, is located external to the rlrA islet, and is 
involved in the regulation of the pili genes. 
 
Gram positive can use pili in the attachment to the host target cell; one model for such an 
attachment is [Telford 2006]: The initial contact with the target cell or extracellular 
matrix (ECM) might be facilitated through an AP2 component on the tip. The properties 
of main pili (and/or AP1) components will then interact with the host target cell and the 
bacteria will be drawn closer to the host cell. This would make it possible for AP1 and 
other non-pili adhesins on the bacterial surface to interact with the receptors on the host 
cells, the result of this would be intimate attachment to and colonization of the host cells 
and tissue. 
 
Expression of pili bacteria might lead to the initial bacterial adherence to host cells, and 
in this way promote colonization of e.g. the nasopharynx [Barocchi et al. 2006]. 
Colonization by pneumococci expressing pili structures more often cause mucosonal 
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infection, this might be triggered by the pili structures, and the structures can aid the 
pneumococci in a potentional invasion of the colonized tissue [Barocchi et al. 2006].  
 
Pili has also shown to promote the aggregation of other bacteria, this might help the 
bacteria to colonize tissues and other surfaces, make the bacteria involved more 
resistance against host defences and allow beneficial interactions between the bacteria 
involved [Telford 2006]. 
 
Pili from enterococci, and other Gram positive, are ideal candidates for vaccines due to 
their exposure on the cell surface. Sera from infected patients have been showed to 
contained antibodies against various surface proteins, among them enterococci pili 
proteins, which indicate that infection, lead to natural production of antibody response to 
enterococci pili. These pili based vaccines cannot be used as general vaccines because of 
the lack of pili in some pathogen strains [Mandlik et al. 2007].  
 
Pili in E. faecium has been suggested to be enriched in hospital-acquired environment, 
indicating that expression of pili might be a selective advantage in this environment, and 
may promote pathogenesis for E. faecium [Hendrickx et al. 2008].  
 
Types of Pili 
In Gram-positives two types of pili have been identified; Fibrils and Pili [Telford et al. 
2006]. Pili are recognized as flexible rods with a length of 0,3-3µm and a diameter of 2-
10nm. There are 2-3 types of pili proteins and 1-4 assembly components, in some                                            
species the assembly is sortase-mediated. The function of the pili is host tissue adhesion, 
co-aggregation and immunomodulation [Telford et al. 2006, table 1].  
The fibrils are 0,07-0,5µm long and has a diameter of 1-2nm, they consists of 2 pili 
proteins and have the same function as the pili, except for the immunomodulation 
[Telford et al. 2006, table 1].  
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In E. faecium PilA has been observed in 40% of the cells, the structure appears as 
relatively short thin rigid appendages highly expressed at the poles of dividing cells 
[Hendrickx et al.. 2008].  Another pili has been identified in E. faecium, the PilB pili, 
which is longer, more flexible, and thicker than the PilA pili structure, it has been 
observed at the poles of the cells, and in single cocci, and PilB are less frequent than PilA 
[Hendrickx et al. 2008].  
 
Assembly of Pili 
There are to models for pili assembly in gram-positive, both are distinctively different 
from how the pili assembly in Gram-negative bacteria, and the first model is supposed to 
be more likely than the second model due to the energy requirements [Telford et al.. 
2006]. Both models explain how the pili are thought to be composed of several proteins 
that are covalently linked into a chain [Scott and Zähner 2006, Telford et al.. 2006]. 
 
Assembly model 1, shown in figure 2: 
This model contains four steps that explain the assembly process which is mediated by 
the sortase catalyzing transpeptidase reactions [Scott & Zähner 2006, Telford et al. 2006] 
and it suggests that the growth happens from the bottom of the structure: 
1. Sec dependent secretion of the three pili proteins, which all contains the LPXTG 
(Leucine- Proline- any amino acid- Threonine- Glycine ) motif and a C-termini 
membrane spanning domain that anchor the protein to the cell membrane. 
2. Cell-anchored proteins are cleaved by a sortase-dependent reaction between the 
threonine (T) and glycine (G) residue in the LPXTG motif. The result is acyl-
enzyme intermediates where covalent thioester bonds are formed between the 
thiol groups of the cysteine residue located in the catalytic site of the sortase 
enzyme and the carboxyl group of the threonine residue in the LPXTG motif in 
the pili protein. 
3. and 4.  oligomerization of the pili protein subunits and the anchoring of the pili to 
the cell wall. These two steps happen due to a nucleophilic attack of the thioester 
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bond that links the threonine residue in the pili protein subunit to the cysteine 
residue in the sortase. 
 
 
Figure 2- showing the pili assembly in Gram-positives. 1) The sec dependent secretion of the pili 
protein over the plasma membrane. 2) Sortase mediated cleavage between the T and G in the 
LPXTG domain, leaving the G, the hydrophobic domain and the positively charged tail behind. 3) 
Oligomerization and anchoring of the structure to the cell wall. 
 
The second model suggests that new pili proteins are added to the top of the pili, growth 
in this way will start with the binding of the first pili subunit to the peptidoglycan 
precursor lipid II. For the addition of a new pili subunit the fiber have to be bent towards 
the membrane in a process that is thought to require energy to promote an effective 
bending of the pili and thereby an effective growth of the pili. Even though electron-
microscopy analyzes have shown pili that lie on the bacterial surface this model is 
thought the less likely of the two because, at the present, there are no clues of where the 
energy for such a bending should come from [Telford et al. 2006]. 
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Sortases and LPXTG motif 
LPXTG proteins, derived from the name of the main conserved residues, x denotes any 
amino acid, is a cell wall sorting motif located at the C-terminal of the surface protein. 
The LPXTG motif is followed by a hydrophobic domain and a positively charged tail that 
is thought to allow the recognition of the LPXTG motif by the sortase by keeping the 
protein from being secreted into the medium [Fischetti et al 1990, Boekhorst et al. 2005]. 
 
Sortases are membrane associated transpeptidases that recognize surface protein 
precursors with a C-terminal cell wall sorting signal (CWSS) containing a pentapeptid 
followed by a hydrophobic region containing 30-40 amino acids and a charged tail [Scott 
& Zähner 2006]. The hydrophobic domain and the charged tail anchor the protein to the 
cell membrane where the sortase is located [Scott & Zähner 2006].  
 
There are four different sortase classes, sortase A, B, C and D, where the main sortases in 
class A and C recognize and cleave at the LPXTG domain [Dramsi et al.. 2008].  
 
Sortase A class is found in almost all low G/C Gram-positive bacteria, and it is believed 
to be required for anchoring the majority of all LPXTG-containing proteins. The sortase 
A class is not clustered with its substrate and is constitutively expressed [Dramsi et al.. 
2008].  
 
The sortase C class is found in both high G/C and low G/C Gram-positive bacteria, often 
represented by several copies in the genome, clustered with the genes for their substrate 
and associated with mobile genetic elements. Unlike sortase class A, sortase class C is a 
polymerizing enzymes that are involved in the formation of pili in Gram-positive 
bacteria, where it catalyzes the formation of the cross-links between two pili subunits 
[Dramsi et al.. 2008]. 
 
Sortase class C cleave the LPXTG domain between the T and the G to form an acyl-
enzyme intermediate, the enzyme is released by a nucleophilic attack by an amino group 
provided by another peptidoglycan precursor for the cell wall anchored proteins, resulting 
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in cleavage and removal of the C-terminal segment from the cell wall anchored protein 
and covalent linkage between the protein and peptidoglycan [Dramsi et al. 2008].  
 
Little is known about the Sec pathway in Gram-positive bacteria. The sec pathway, in 
general, is an exocytic pathway, which means that the cell secrete molecules using this 
pathway, the pathway coordinates the biosynthesis and secretion of bacterial molecules 
[Pollard and Earnshaw 2004]. 
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Nomenclature of the Putative Main Pili Genes 
Pili in E. faecium have been identified in silico in four gene clusters, PGC1, PGC2, PGC3 
and PGC4 [Hendrickx 2008]. 
 
There has been an attempt for establishing names for the presumed main pili genes. 
Hendrickx et al. [2008] uses pilA about the putative main pili in PGC1, and pilB about 
the putative main pili in PGC3.  
 
In this thesis the work has been concentrated on PGC2 and PGC3, the main pili are, from 
now on, in this thesis called C3:44, which are located in PGC2, and C3:48, which are 
located in PGC3, and is the same as pilB. The screenings have been done on the gene 
encoding pili1:44 in PGC2, and it will be referred to as pili 1:44. For the screening for 
PGC3 pili 1:48 was used, and it will be referred to as pili 1:48. 
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Aims of this Study 
The overall objectives with this study were to detect pili structures in E. faecium by 
electron microscopy, and the second aim was to screen for putative pili genes in given 
invasive and non-invasive strains of E. faecium. 
 
The work was defined into five steps: 
1) To design PCR tools for amplification of putative pili coding sequences from E. 
faecium. 
2) To perform TOPO-cloning of amplicons into pENTR-vector by directional 
insertion. 
3) To purify the putative pili proteins by affinity chromatography and inject rabbits 
for production of polyclonal antibodies. 
4) To detect pili by electron microscopy with immunogold labeling. 








The kits used are in table 1 
 




E.Z.N.A D6945-02 Plasmid Mini Kit II 
E.Z.N.A D6943-02 Plasmid Mini Kit I 
Invitrogen K2420-20 pENTRTM Directional TOPO® Cloning Kits 
Invitrogen 11824-0261) E. coli Expression System with Gateway® Technology 
Invitrogen LC6033 InVisionTM His-Tag In-gel Stain 
1) There are several kits covered in the protocols, catalogue number is registered for the kit used in 
this thesis. 
 
Chemicals used in the experiments are in table 2; this table also includes enzymes, 
buffers and antibodies ordered from an external provider. 
 
Table 2- Chemicals, enzymes and buffers used in the work for this thesis. 
Provider Catalogue nr1) Enzyme/ Chemicals 
Invitrogen 11791-020 Gateway LR Clonase Enzyme Mix 
USB - Exonuclease I (Exo) 
USB - Shrimp Alkaline phophatase (SAP) 
Invitrogen NP0007 NuPAGE LDS Sample Buffer 
Invitrogen NP0005 NuPAGE Antioxidant 
Invitrogen NP0005 Antioxidant 
Roche 13279400 25mM MgCl2 
Thermo Scientific AB0575/DC/LD/B ReadyMix PCR mastermix 
Sigma  092K8930 EtBr 
Applied biosystems - BigDye 3.1 
Applied biosystems - BigDye Sequencing Buffer 
Qiagen  Penta-His HRP Conjugate 
Sigma Aldrich EC200-664-3 DMSO 
Arcus Kjemi  600068 Absolute Alkohol Prime 
BDH laboratory supplies   663684B Tween 20 
BDH laboratory supplies  306324N Triton x-100 
Invitrogen NP0002 NuPAGE  Running buffer 20x 
1) The lab has replaced Exo and SAP with a ready to use ExoSAP, catalogue number for the 
products depends on the volume of the enzymes, and this also applies on the BigDye 3.1 and BigDye 
Sequencing buffer.  
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Molecular Weight Standards 
Table 3 gives an overview over the used molecular weight standards, figure 3 and 4 
shows the band sizes of 1kb+ and MagicMarker molecular standards, and these were the 
molecular standards used to check the size of the PCR product and protein, respectively. 
 




Invitrogen LC5677 Mark12 Unstained Standard 
Invitrogen LC5602 MagicMarker XP Western Standard
Invitrogen LC5925 SeeBlue 2 Marker 





Figure 3 - 1kb+ molecular weight standard, figure from invitrogen.com. 
 
 
Figure 4- MagicMarker Molecular weight standard from Invitrogen. Picture from invitrogen.com. 
The bands are visualized with comassie blue. 
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Vectors and competent cells 
The competent cells and vectors used in this thesis are in table 4. 
Table 4- The competent cells and vectors used. 
Provider Catalogue nr Cells/ vectors 
Invitrogen C6070-03 OneShot BL21-AI Chemically competent cells
Invitrogen Provided by kit K2420-20 OneShot TOP10 Chemically competent cells
Made in the department - DH5α Chemically Competent cells 
Invitrogen Provided by kit K2420-20 pENTR entry vector 
Purified from cells - pDEST17 expression vector 
 
DH5α chemically competent cells are suitable for maintaining plasmids over time due to 
their recA1 and endA1 mutations which increase insert stability and quality of plasmids 
purified by minipreps. In addition to this DH5α cells can be used in blue white screening 
due to the presence of lacZ∆M15 promoter [invitrogen.com]. 
 
OneShot TOP10 chemically competent cells allow stable replication and maintaining of 
plasmids, they take up unmetylated DNA, like PCR products, effectively during 
transformation. They can also be used in blue-white screening due to the presence of 
lacZ∆M15 promoter [invitrogen.com]. 
 
OneShot BL21-AITM Strain is designed for expression of recombinant proteins from the 
T7 promoter, the expression from this promoter can be tightly regulated by L-arabinose 
and glucose [E. coli Expression with Gateway® Technology protocol]. 
 
The pENTRTM/SD/D-TOPO® vector contains a gene 10 translational enhancer, a 
ribosome binding site (RBS), a T7 promoter/priming site, M13 forward (-20) and reverse 
priming sites, attL 1 and 2 and NotI [pENTRTM Directional TOPO® Cloning Kits], as 
indicated in figure 5. The figure also shows the location of selective gene, kanamycin 
resistance, origin of replication and T2 and T1. 
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Figure 5- The pENTR/SD/D- TOPO® vector [http://www.emblhamburg.de/~geerlof/webPP 
/genetoprotein/cloning_strategy/gateway/ENTR_vectors/pentrsd_dtopo_map.pdf] 
 
The sequence in figure 6 was used to make primers for the cloning into the vector. The 
restriction sites are marked, and the darker region will be transferred to pDEST via LR 
recombination between the vectors. 
 




The pDESTTM17 are N-terminal fusion vectors that contain an ATG initiation codon 
upstream of the GST and 6xHis tags. Shine-Dalgarno is located upstream for the ATG, 
and the T7 promoter and transcriptional start is located upstream for the Shine-Dalgarno. 
The attachment sites, attB1 and attB2, are located downstream for the 6xHis tags, as 
indicated in figure 7. The gene of interest is recombined in between the two attachment 
sites. Figure 7 also shows the location of the selective gene ampicillin resistance, origin 
of replication (ori) and rop. [E. coli Expression System with Gateway® Technology] 
 
 
Figure 7- The pDESTTM vector [http://ecoliwiki.net/colipedia/images/thumb/5/5f/Pdest_17.jpg/440px-
Pdest_17.jpg] 
 









Blocking buffer (20 ml)3: 
Blocking reagent   0,1 g  
Blocking reagent buffer 20 ml 
Heat to 70ºC 
10% Tween 20  200 µl 
 
Blotting buffer (10X) 
Glycine   144 g 
Tris base   30,3 g 
Distilled water to 1 L 
 
Blotting buffer (1X) 
Blotting buffer 10X  50 ml 
Deionised water  450 ml 
 
                                                 
3 See QIAexpress Detection and Assay handbook 10/2002 protocol 7, Immunodetection with Anti-his 
Antibodies or Anti-His HRP conjugate (Chemiluminicent method) 
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Fixing solution for NuPAGE Novex gels 
Ethanol   40ml 
Acetic acid   10ml 
Distilled water to   100ml 
 
Lysis Buffer 
Potassium phosphate, pH7,8 50 mM 
NaCl    400 mM 
Glycerol   10% 
Triton X-100   0,5% 
Imidazole   10 mM 
 
NuPAGE MES running buffer 1X 
NuPAGE MES  40 ml 
Running buffer (20X) 
[Invitrogen catalogue number NP0002] 
Distilled water   760 ml 
 
Phophate buffer, 20mM 
Sodium phosphate   2,6g 
(monobasic) 
Adjust pH to 7,8 with 3M NaOH 
Distilled water to 1000ml 
 
TBS (10X) 
Trizama HCl   24,3 g 
NaCl    80,06 g 
Distilled water  800 ml 
pH adjusted to 7,6 





TBS 10X   100ml 
Deionised water  899ml 
Tween 20       1ml 
 
TBST + Triton (0,5 L)4
TBST    0,5 ml 
Triton x-100   1 ml 
 
TE buffer 
1 M HCl pH8   20 ml 
0,5 M EDTA   4ml 
Distilled water up to 2 L 
 
                                                 
4 See QIAexpress Detection and Assay handbook 10/2002 protocol 7, Immunodetection with Anti-his 
Antibodies or Anti-His HRP conjugate (Chemiluminicent method) 
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Media 
Blood Agar  
Blood Agar Base Oxoid CM 271    40 g   
Distilled water                                  1 L          
 
LB medium and plates 
Tryptone    1,0% 
Yeast extract      0,5% 
NaCl     1,0% 
pH     7,0 
 
For LB medium and plates with antibiotics: 
Kanamycin    50 µg/ml 
Ampicillin    100 µg/ml 
 
S.O.C. 
Deionised water   950ml 
Tryptone    20g 
Yeast extract    5g 
NaCl     0,5g 




The primers used are in table 5, the reverse primers are showed as the primer sequence 
and as reverse complement. 
 
Table 5 - Primers used in the experiments. 
Primer Sequence Reverse complement of reverse primers 
Pili 1:44 F CGGGAGCTCAAGACGGAA - 
Pili 1:44 R TAACTGATAACGTGGTGGTCCA TGGACCACCACGTTATCAGTTA 
Pili 2:44 F AACCGAGGAACTGCAAGAGA - 
Pili 2:44 R  GCGGATTCATAGGCAGAGAC GTCTCTGCCTATGAATCCGC 
Pili 3:44 F ATGAAGCTGGAGAAGCGGTA - 
Pili 3:44 R CGCTTCCGTTTTCAAGGACA TGTCCTTGAAAACGGAAGCG 
Pili C3:44 F  CACCATGAGTGTACTGTTACTCGTTACTG - 
Pili C3:44 R1  TTATACTTCAGACTTCATTTTAGATTTAC GTAAATCTAAAATGAAGTCTGAAGTATAA 
Pili C3:44 R2 TACTTCAGACTTCATTTTAGATTTACG CGTAAATCTAAAATGAAGTCTGAAGTA 
Pili 3:44 FR GAAAGTCACAACAGGTGGA - 
Pili 3:44 FM CCAGAATCGCGTCTCCA - 
Pili 3:44 RL CCATGTAGAACCATCCCACA TGTGGGATGGTTCTACATGG 
Pili 3:44 RM GGTCTTCATTCCACAATTCGA TCGAATTGTGGAATGAAGACC 
Pili 1:48 F GAAAATGAGGACTTCCATCCAA - 
Pili 1:48 R ATCCTTTTCACCTGTAGAGGAA TTCCTCTACAGGTGAAAAGGAT 
Pili 2:48 F GCACAAGCAGAGATCGCAA - 
Pili 2:48 R CCGCACTATCTGACAATTCGA TCGAATTGTCAGATAGTGCGG 
Pili 3:48 F TTTGAACGAAAAAGCAGATCCA - 
Pili 3:48 R GCCATATTTTAGACCTGTCACA TGTGACAGGTCTAAAATATGGC 
Pili C3:48 F CACCATGTTAGGAGTCCTTTTCCTTATTT - 
Pili C3:48 R1 CTAAATCTGACTGTGCTTGCG  CGCAAGCACAGCTAGATTTAG 
Pili C3:48 R2 AATCTGACTGTGCTTGCGTC GACGCAAGCACAGTCAGATT 
Pili 3:48 RL TCTAGTTCTTCTGTCCCGTA TACGGGACAGAAGAACTAGA 
Pili 3:48 FM ACCAAAAGACGGAGTGTCA - 
Pili 3:48 RM GCAGCGTCATGAGTATCGA TCGATACTCATGACGCTGC 
Pili 3:48 FR GATCCTGGCAAATAGCCAA - 
M13 F GTAAAACGACGGCCAG - 
M13 R CAGGAAACAGCTATGAC GTCATAGCTGTTTCCTG 
 
Figure 9 gives an overview of the pili operon, the figure is based on the pili operon from 
the pathogenicity islet in pneumococci 
 
Figure 9- The pili operon in the rlr islet. 
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Figure 10 shows an overview of the suspected orf of the main pili, it is based on the 
operon in figure 9 and is the rrgC gene in that figure. The figure includes the primers 
used for sequencing of the orfs, and each primer pair has the same color. M13 primers 
were located in the vector, outside the gene. 
 
Figure 10- The suspected pili 1:44 rrgC orf with primer localization and the suspected pili 
1:48 rrgC orf with primer localization.  
 
Table 6 shows the position of the primer and their function in the experiments, for the Pili 
44 primers the position is in operon 44, and for the Pili 48 primers the position is in 
operon 48 [Enterococcus faecium DO JGI 4/6/04 Assembly] 
 







Pili 1:44F/ Pili 1:44R 3038-3055 3387-3408 Screening 
Pili 1:48F/ Pili 1:48R 4205-4226 4705-4726 Screening 
M13F/ Pili3:44RL in the vector 7022-7041 Sequencing 
Pili 3:44FM/ Pili 3:44RM 6959-6975 7698-7718 Sequencing 
Pili 3:44FR/ M13R 7624-7642 in the vector Sequencing 
M13F/ Pili3:48RL in the vector 7709-7728 Sequencing 
Pili 3:48FM/ Pili 3:48RM 7619-7638 8301-8319 Sequencing 
Pili 3:48FR/ Pili 3:48R 8104-8122 8803-8824 Sequencing 
Pili 3:48F/ M13R 8503-8524 in the vector Sequencing 
Pili C3:44F/ Pili C3:44 R1 6468-6499 8121-8149 Cloning 




The isolates used for screening for the pili 1:44 and pili 1:48 genes are noted in table 7. 
Other strains used were E. faecium DO for positive control, Staphylococcus epidermis as 
negative control. E. faecium BM 4105RF and E. faecium 64/3 were used in the designing 
of PCR tools. 
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Table 7- Isolates used for screening, showing the 96 well setup. 
Well 
Reference 







1a TUH 44-39 399/F99/A9 
(248) 
Norway/Østfold Animal Faeces Community 
survey 
VanA Johansen et al. 2003 
1b TUH 44-29 399/F99/H8 
(106) 
Norway/ Østfold Human Faeces Community 
survey 
VanA (Johensen et al. 
2003)/AMV 
1c TUH 44-34 399/F98/A4 
(225) 
Norway/ Østfold Animal Faeces Community 
survey 
VanA Johensen et al. 2003 
1d TUH 7-57 BM4147 France Human Faeces Clinical isolate VanA Leclercq et al. 1988 
1e TUH 7-58 BM4147-1 France Human Faeces Curing of 
BM4147 
- Leclercq et al. 1988 
1f TUH 41-64 U37 (pRUM) USA/ Ohio Human   Clinical isolate - Grady et al. 2003 
1g TUH 12-1 C 68 USA / Ohio Human Faeces Clinical isolate VanB (Carias et al. 2003, Dhal 
et al. 2000) 
1h TUH 12-16 64/3 Germany/IN Human Faeces IN - Wolfgang Witte/AMV 
2a TUH 12-4 3332 USA/ Ohio Human DN Outbreak VanB (Carias et al. 2003, Dhal 
et al. 2000) 
2b TUH 2-18 25942/96 Norway/ Bergen Human Urine Outbreak VanB Mikalsen, M. R./AMV 
2c TUH 2-19 28865/96 Norway/ Bergen Human Wound Outbreak VanB Mikalsen, M. R./AMV 
2d TUH 2-21 17112/96 Norway/ Bergen Human IN Outbreak - Mikalsen, M. R./AMV 
2e TUH 2-8 95 T0070 Sweden/ Ørebro Human Faeces Clinical isolate VanA Mikalsen, M. R./AMV 
2f TUH 32-56 DO (TX0016) 
(TEX16) 
USA/ Houston Human Blood Clinical isolate - Arduino et al. 1994 
2g TUH 32-61 E1293 (10A243) Italy/ Genua Human Blood Clinical isolate - Willems, R. J. L. 




Human Blood Hospital 
outbreak 
VanB Willems, R. J. L. 
3a TUH 32-63 E1626 (85/65) Netherlands/IN Human Peritoneal 
fluid 
Clinical isolate - Willems, R. J. L. 
3b TUH 32-64 E0013 (58155) Great Britain/ 
Oxford 
Human Urine Hospital 
outbreak 
VanA Willems, R. J. L. 
3c TUH 32-65 E1272 (05A433) France/ Lyon Human Blood Clinical isolate - Willems, R. J. L. 
3d TUH 32-66 E1279 (07A217) Denmark/ 
Freiburg 
Human Blood Clinical isolate - Willems, R. J. L. 
3e TUH 32-67 E0403 (SKH26) Netherlands/IN Human Faeces Community 
survey 
VanA Willems, R. J. L. 
3f TUH 32-68 E0996 
(9800265E) 
Netherlands/IN Human Faeces Community 
survey 
- Willems, R. J. L. 






VanA Willems, R. J. L. 








VanA Willems, R. J. L. 




Human Faeces Hospital 
outbreak 
VanA Willems, R. J. L. 
4b TUH 32-72 E0155 (VS2) USA/ Chicago Human Faeces Hospital 
outbreak 
VanA Willems, R. J. L. 




Human Faeces Hospital 
outbreak 
VanA Willems, R. J. L. 
4d TUH 32-74 E0300 (Detroit 
12) 
USA/ Detroit Human Urine Hospital 
outbreak 
VanA Willems, R. J. L. 




Human Faeces Clinical isolate VanA Willems, R. J. L. 
4f TUH 32-76 E1304 (15A159) Portugal/ 
Coimbra 
Human Blood Clinical isolate VanA Willems, R. J. L. 




Clinical isolate VanA Willems, R. J. L. 




Human Bile Clinical isolate VanA Willems, R. J. L. 
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Table 7- Continued 
Well 
Reference 







5a TUH 32-79 E0729 (A155) Netherlands/ 
Amersfoort 
Human Faeces Hospital survey VanA Willems, R. J. L. 
5b TUH 32-80 E0092 (9700228) Netherlands/IN Human Faeces Community survey VanA Willems, R. J. L. 
5c TUH 340   Norway/ Østfold Animal Faeces Community survey - AMV 
5d TUH 4-15 ATCC 19434 
(NCTC 7171) 
IN/IN* IN IN IN - ATCC 
5e TUH 4-21 94 I Norway/ Øsfold Animal Chicken 
meat 
Community survey VanA Mikalsen, M. 
R./AMV 
5f TUH 4-22 111 III Norway/ Øsfold Animal ? Chicken 
floor 
Community survey VanA Mikalsen, M. 
R./AMV 
5g TUH 4-41 Bm 4105- RF France/IN Animal Faeces Wild strain - (3)/AMV 
5h TUH 4-65 E57-1 USA/IN Human IN IN VanB Dahl et al. 1999
6a TUH 44-23 399/F98/H2 (95) Norway/ Østfold Human Faeces Community survey VanA 20 Aasnæs, B 
6b TUH 44-31 399/F98/A1 (222) Norway/ Østfold Animal Faeces Community survey VanA Johnsen et al.
2005
6c TUH 44-40 399/F99/A10 (241) Norway/ Østfold Animal Faeces Community survey VanA Johnsen et al.
2005
6d 





























(Johnsen et al. 
2005)/AMV 
6h 













(Johnsen et al. 
2005)/AMV 
7b 





























(Johnsen et al. 
2005)/AMV 
7f 





(Johnsen et al. 
2005)/AMV 
7g TUH 7-15 110-1309-1 USA/IN Human Blood Outbreak VanB Dahl et al. 1995
7h TUH 7-55 UW 1551 Germany/IN Human Urine Clinical isolate VanB Dahl et al. 1995
8a TUH D2-34 D34 Denmark/ Aarhus Human Blood Clinical isolate - Simonsen et al.
2003
8b TUH D2-6 D6 Denmark/ Aarhus Human Blood Clinical isolate - Simonsen et al.
2003
8c TUH D2-69 D69 Denmark/ Aarhus Human Urine Clinical isolate - Simonsen et al.
2003
8d TUH D2-91 D91 Denmark/ Aarhus Human Blood Clinical isolate - Simonsen et al.
2003
8e TUH I1-82   Iceland/ 
Reykjavik 
Human Blood Clinical isolate - Simonsen et al.
2003
8f TUH N1-42   Norway/ Bergen Human Urine Clinical isolate - Simonsen et al.
2003
8g TUH N1-59   Norway/ Bergen Human Urine Clinical isolate - Simonsen et al.
2003




Table 7 Continued 
Well 
Reference 







9a TUH N1-90   Norway/ Bergen Human Blood Clinical isolate - Simonsen et al. 2003
9b TUH N2-1   Norway/ Tromsø Human Urine Clinical isolate - Simonsen et al. 2003
9c TUH N2-26   Norway/ Tromsø Human Urine Clinical isolate - Simonsen et al. 2003
9d TUH N2-78   Norway/ Tromsø Human Blood Clinical isolate - Simonsen et al. 2003
9e TUH N2-85   Norway/ Tromsø Human Blood Clinical isolate - Simonsen et al. 2003
9f TUH S1-102   Sweden/ Uppsala Human Urine Clinical isolate - Simonsen et al. 2003
9g TUH S1-28   Sweden/ Uppsala Human Blood Clinical isolate - Simonsen et al. 2003
9h TUH S1-7   Sweden/ Uppsala Human Blood Clinical isolate - Simonsen et al. 2003
10a TUH S1-95   Sweden/ Uppsala Human Urine Clinical isolate - Simonsen et al. 2003
10b K8-42 V1-59 Norway/ Oslo Human Faeces Clinical isolate VanA K-res 
10c K8-43 V1-60 Norway/ Oslo Human Faeces Clinical isolate VanA K-res 
10d K8-45   Norway/ 
Kristiansand 
Human Urine Clinical isolate VanA K-res 
10e K9-26   Norway/ 
Kristiansand 
Human Faeces Clinical isolate VanA K-res 
10f K9-27   Norway/ 
Kristiansand 
Human Faeces Clinical isolate VanA K-res 
10g K9-28   Norway/ 
Kristiansand 
Human Faeces Clinical isolate VanA K-res 
10h K9-72   Norway/ Ålesund Human Faeces Clinical isolate VanA K-res 
11a K8-50 14-4, 25509/99 Norway/ Ålesund Human Urine Clinical isolate VanA Simonsen, G 
11b TUH 2-40 14-5, 
39487covIII 
Norway/ Oslo Human Faeces Clinical isolate VanA Simonsen, G 
11c TUH 2-13 14-7, 273-78 Norway/ SIR Human UVI Clinical isolate VanA Simonsen, G 
11d TUH 7-56 14-13 Norway/ DNR Human Faeces Clinical isolate VanA Simonsen, G 
11e K8-61 14-16, 1049698-
1/98 
Norway/ Bergen Human ? Clinical isolate VanA Simonsen, G 
11f K8-62 14-17, 1105035-
3/99 
Norway/ Bergen Human ? Clinical isolate VanA Simonsen, G 
11g K8-64 Prøvenr UNN 
80728/01 
Norway/ Akershus Human Faeces Hospital survey VanB2 Halvorsen, D 
11h K8-74 Prøvenr UNN 
24024/02 
Norway/ Akertshus Human Faeces Hospital survey VanA Halvorsen, D 
12a K8-69 Prøvenr UNN 
134568/01 
Norway/ Akershus Human Faeces Hospital survey VanA Halvorsen, D 
12b K8-68 Prøvenr UNN 
109480/01 
Norway/ Akershus Human Faeces Hospital survey VanA Halvorsen, D 
12c K9-10 Prøvenr UNN 
121311/02 
Norway/ Akershus Human Faeces Hospital survey VanA Halvorsen, D 
12d K18-79 Prøvenr St.Olavs 
50144 
Norway/ St.Olavs Human Faeces Hospital survey VanA Halvorsen, D 
12e 41-73 EA-AN26 Italy Animal Faeces ? VanA AMV 
12f Control Negative control 1:44, Positive Control 1:48 
12g Control Positive control 1:44, Mastermix control 1:48 
12h Control Mastermix control 1:44, Negative control 1:48 
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Other materials used 
Table 8 notes the machines used for the work, it includes analytical machines like the 
spectrophotometer. 
 
Table 8 - Machines 
Provider Machine 
M7 Research PTC-200 
Heraeus Biofuge pico 
New Brunswitch scientific Incubator shaker 
Not known E-base 
Not known Electrophoresis 
Pharmacia Biotech Spectrophotometer, ultrospec 2000 
Not known Western Blot 
 
 
For analyzing the lab results some computer work had to be done, table 9 gives an 
overview of the software used. 
 




Synoptics Ltd SynGene 
Thermo Fisher Scientific NanoDrop 
 
Gels, tubes and other basic materials used in the work for this thesis is shown in table 10 
 
Table 10- Other stuff used. 
Provider Catalogue nr Other 
Applied BioSystems 4306737 MicroAmp 
AB gene AB 0337 0,2ml eppendorf tube 
  1,5ml eppendorf tube 
Invitrogen G7008-02 E-Gel 96 2% agarose (GP) 
Invitrogen NP0322BOX NuPAGE 4-12% Bis-Tris Gel, 1,0mm, 12 well 
-  dry ice 
  Agarose 
Thermo Scientific AB-0266 0,2ml thermo-strip 
Whatman 708111 Protran BA 85 Nitrocellulose 
Roche 11666916001 Chemiluminicent Detection film 
- - PCR Film 
Whatman 3030917 3mm Chromatography paper (filter paper) 
-  Blotting Pads 
Amershman biosciences  HyperCassette 
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Methods 
Figure 11 shows the flow in the experiments 
Figure 11 A 
Designing of PCR tools for cloning. 
 
 
Cloning into pENTR vector, check for inserts and purification of plasmid with 
insert. 
 
Sequencing to check ends and orientation of the region to be cloned. 
 
 
Recombination between the pENTR and pDEST vectors to move insert into 




Plasmids purified from DH5α cells for transformation into BL21-AI 
competent cells for expression. 
 
Expression of protein in BL21-AI cells, segregation of water insoluble and 




Western blot and detection to see which fraction the protein is located in.  
 
 
Figure 11 B 









Over night cultures for crude DNA extraction was made by plating out bacteria from the 
freeze storage. Cells were kept from thawing by incubation on ice and minimum hand 
contact. By scraping the ice surface with a needle it was possible to transfer a few 
bacteria from the tube to the plate with non-selective media. Selective media was used 
when necessary for maintaining vector and constructs. 
 
Each bacterial isolate has an In House identification number, and this number was used to 
find the bacteria. 
 
Over night cultures were inoculated from single colonies on plates. One single colony 
was picked up by an inoculation needle and transferred to a tube containing selective 
medium. The cells were incubated at 37˚C over night, shaking at 200 rpm in an 
incubation shaker. 
 
Freezing of Cell Cultures 
Procedure 
930µl overnight culture containing selective antibiotic was mixed with 70µl DMSO and 
stored at –80ºC. 
 
DNA Isolation 
Crude Extracts of Total DNA 
Boiling overnight cultures in a solution like TE buffer causes the cell wall to break and 
the DNA will be released in sufficient quantity and purity for PCR amplification. The 
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DNA is separated from the rest of the cell by centrifugation; the DNA will be in the 
supernatant and the pellet contains the rest of the cell. 
 
Procedure 
1) 8-10 single colonies from one plate was collected and dissolved in 1000µl TE 
buffer in 1,5 ml eppendorf tubes. The tubes were labelled with the strain name. 
2) The suspension was centrifuged for 5 min at 2012xg. 
3) The supernatant was removed, and the pellet was resuspended in 100µl TE buffer. 
4) The suspension was then boiled for 10 min at 100ºC, before the boiling the lids 
were pierced. 
5) The suspension was centrifuged for 5 min at 2012xg, and put on ice. 
6) The supernatant, containing the DNA, was transferred to a new, clean 1,5ml 
eppendorf tube and stored at -20˚C. 
 
Plasmid Extraction 
Plasmids are relatively small DNA molecules and does not precipitate at the same salt 
concentrations as chromosomal DNA, this quality can be used to purify plasmids from 
chromosomal DNA. By adding a salt solution to the cells, the cells will lyse, and after 
centrifugation chromosomal DNA will be in the pellet while plasmids will be in the 
supernatant. [Snyder & Champness 2007]. E.Z.N.A uses this combined with a column 
binding the plasmids, centrifugation causes the chromosomal DNA to go through the 
column with the flow through. The plasmids can be eluted from the column by using an 
elution buffer with a low salt concentration, or using water. 
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High copy number 
This was done by E.Z.N.A.TM Plasmid Miniprep Kit II 
 
Procedure 
1) Single overnight colonies from selective plates was picked up and added to 10-15 
ml selective medium. The cultures were incubated over night at 37˚C, shaking at 
200 rpm in an incubation shaker. Kanamycin was used as selective marker in the 
TOPO® cloning. 
2) 1000µl overnight culture was centrifuged in room temperature for 10 minutes at 
2012xg to pellet the cells. The supernatant (medium) was discarded. 
3) The pellet (cells) was completely resuspended in 500µl Solution I/RNase A 
solution by pipetting up and down. 
4) The resuspended cells were transferred to two clean 1,5ml eppendorf tubes, 250µl 
too each. 
5) 250µl Solution II was transferred to each eppendorf tube and mixed gently by 
inverting and rotating the tube several times to get a clear lysate. In some cases it 
was necessary with 2 - 5 minutes incubation at room temperature, but the lysis 
reaction should not go on for more than 5 minutes. 
6) 350µl Solution III was added and rapidly mixed with the lysate, by rotating and 
inverting the tube, until a flocculent with precipate formed. 
7) The tubes were centrifuged at 13600 xg to pellet the cell debris. The supernatant 
was transferred to a clean HiBind® Miniprep column (II) that was placed in a 2ml 
collection tube, one column for each sample. The columns were centrifuged at 
13600 xg for 1 minute at room temperature to pass the lysate through the column. 
The flow-through was discarded and the rest of the lysate was added to the 
column. The columns were centrifuged at 13600 xg. 
8) Flow-through was discarded and 500µl buffer HB was added to wash the HiBind® 
Miniprep column (II). The columns were centrifuged at 13600 xg for 1 minute to 
pass the lysate through the column. 
9) Flow-through was discarded and 700µl DNA wash buffer diluted with absolute 
ethanol was added to the columns. The columns were centrifuged at room 
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temperature for 1 minute at 13600 xg to pass the lysate through the columns. This 
step was done twice. 
10) The empty columns were centrifuged for 2 minutes at 13600 xg at room 
temperature to dry the column matrix. 
11) The columns were placed in clean 1,5ml eppendorf tubes without caps, 100µl 
elution buffer was added to the column matrix and the columns were centrifuged 
for 1 minute at 13600 xg in room temperature to elute the DNA. 
12) The concentration of DNA was estimated by NanoDrop. Elution buffer was used 
as blank. 
13) DNA was maintained by freezing it at -20˚C. 
 
Low copy number plasmids 
This was done by E.Z.N.A.TM Plasmid Miniprep Kit I 
 
Procedure 
1) Single colonies from an overnight selective plate with 100µg/ml ampicillin used 
to inoculate starter cultures if 5 ml LB medium containing 100µg/ml ampicillin. 
The starter cultures were incubated over night in room temperature, shaking at 
200 rpm in an incubation shaker. 
2) 1000µl culture were centrifuged at 10000xg for 2 minutes to make a cell pellet, 
the supernatant were discarded. 
3) The cell pellet was resuspended in 250µl SolutionI/ RNase A solution, this was 
done by pipetting up and down until the whole pellet was dissolved. The 
suspension was transferred into a clean 1,5µl eppendorf tube. 
4) 250µl Solution II was added to the suspension and mixed by inverting the tube 
gently several times, until a clear lysate was obtained. Vigorously mixing would 
shear chromosomal DNA and lower plasmid purity. The reaction did not go for 
more than 5 minutes! 
5) 350µl of Solution III was added and the tube was inverted several times until a 
white flocculent precipitate formed. 
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6) Centrifuge at 13000xg for 10 minutes at room temperature. Put HiBind Miniprep 
Columns (I) was put in clean 2ml collection tubes. 
7) The clear supernatant was carefully added to a clean HiBind Miniprep Column 
(I). Centrifuge for 1 minute at 13600 xg at room temperature. 
8) Flow through was discarded and 500µl buffer HB was added to wash the HiBind 
Miniprep Column (I). Centrifuge at 13600 xg for 1 minute at room temperature. 
9) Flow- through was discarded and 700µl of DNA wash buffer diluted with 
absolute ethanol before use, was added to the column. The column was 
centrifuged at 13600 xg for 1 minute at room temperature. 
10) Step 9) was repeated 
11) The empty column was centrifuged at 13600 xg for 1 minute at room temperature. 
12) The column was placed in a 1.8µl eppendorf tube (the lid was marked and 
removed, and taken care of for use when the plasmid isolation was finished).  
50µl – 100µl5 elution buffer. The column was centrifuged at 13600xg for 1 
minute at room temperature. 
13) Yield and quality of isolated plasmid was determined by NanoDrop, elution 
buffer was used as blank. 
14) The isolated plasmids were stored at -20˚C. 
 
Amplification Detection and Determination of DNA Sequences 
Amplification of Pili Genes by Polymerase Chain Reaction (PCR)  
The polymerase chain reaction copies a section of double stranded DNA, and its power 
lies in the possibility to produce a large number of copies of the target DNA sequence in 
a short period of time. Normally the primers flanking the DNA target sequence have a 
length of 17-30 nucleotides and have approximately the same sequence as the strand they 
are binding to; one primer will bind to the leading strand, while the other will bind to the 
lagging strand. [Reece 2004] 
                                                 
5 Most often 80µl was used, and when possible a gradient with volumes 50µl, 70/80µl and 100µl were used. 
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The PCR reaction goes through three different steps; denaturation, annealing and 
elongation, these steps make up a cycle that is repeated 20-35 times to achieve a 
satisfying amount of amplified DNA [Reece 2004]. 
 
Procedure 
1) Mastermix was made; table 11 shows the recipe for the mastermix used in this 
experiment. Primers were the last things added to the mastermix. The reagents 
was diluted according to manufactures recommendation,  
 
Table 11- PCR reaction mastermix for nine samples with a total volume of 25µl 
Reagent Volume  
ReadyMixTM 125 µl 
Primer F 25µl 
Primer R 25µl 




2) The primers were optimized by using a temperature gradient ranging from 53ºC to 
66ºC, the lowest temperature with a positive + control, and a negative – control 
was registered as the optimal temperature for the primers. 
3) Mastermix and DNA template was mixed by centrifuging in PCR tubes. 22µl 
mastermix was added to the tubes, then 3µl template to make a reaction solution 
with a total volume of 25µl. Table 12 (next page) shows the PCR programs used 
in this experiment. 
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1) PCR programs that were optimized 
2) Each program started with a 1 minute denaturation at 95˚C, and after the cycles the 
programs ended with a 4 minutes elongation at 72˚C followed by a 4˚C unlimited hold. 
Temperatures in clams show the primer pairs temperature range. 
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Detection of PCR Products by Agarosegel Electrophoreses 
Dry agarose suspended in a buffer, i.e. 0,5X TBE, and boiled to make a clear solution of 
agar that will form a gel when the temperature gets beneath 50˚C. The pore sizes in 
agarosegels cannot be accurately controlled, and therefore the bands will be less distinct 
than the bands in gels were the pore size can be controlled [Reece 2004]. 
 
The movement of the fragments is decided by several parameters; size, shape and agarose 
concentration are the most important parameters. The running time and electrical current 
are also important and controllable parameters. Agarose gels can separate DNA 
fragments in the size range of 200-15000 base pairs [Reece 2004]. 
 
Visualization of DNA in the agarose gels are done by staining the DNA fragments, this is 
most commonly done by soaking the gel in Etidium bromide (EtBr) [Reece 2004], but 
because of the carcinogenic effects of EtBr other substances such as cyber safe should be 
used. EtBr is a flat planar molecule that can intercalate between stacked pairs of DNA 
and bind efficiently, this result in a distortion of the DNA double helix and localized 
unwinding of the structure. EtBr binds less efficiently to single stranded DNA and RNA 
due to the relative lack of stacking in these molecules [Reece2004]. In UV light EtBr-
DNA shows up as light bands. 
 
Procedure 
1) Dry agarose was added to in 0,5X TBE buffer (made from a 10X stock solution), 
for a 40ml 0,8% gel 0,32 g was dissolved in 40ml buffer and for a 60ml 0,8% gel 
0,48 g was dissolved in buffer. Because of evaporation when the mixture was 
boiled 3-4 ml extra buffer was needed. 
2) This solution was boiled in a microwave to dissolve all the agarose, the solution 
was taken out and carefully shaken once in a while, and after boiling. It was 
allowed to boil 2-3 times to ensure that all agarose was dissolved. 
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3) The solution was allowed to cool to about 40ºC before EtBr was added to a final 
concentration of 0,5 µg/ml. The gel was cast, and allowed to set before the 
samples was loaded. 
4) Each well was loaded with 10µl sample, and the first and the last well loaded with 
3,5µl 1kb+ molecular weight standard with DNA of known sizes. The samples 
included PCR products from a mastermix control (H2O), a negative control (a 
staphylococci, in house number 6-01) and a positive control (E. faecium DO, 32-
56). 
5) 0,5X TBE buffer was used as electrophoresis buffer. The running parameters 
were 120V for 45 min. 
6) After the electrophoresis the gel was exposed to UV light to detect the DNA. The 
bands were compared to the 1kb+ molecular weight standard to decide the size of 
the products, and to see if the products might be the DNA of interest. 
 
DNA sequencing 
The sequencing was done using the procedure provided by the sequencing lab at the 
University of Tromsø. 
 
Before the sequencing of PCR products primers and the remains of dNTPs should be 
removed to get rid of some potential contaminants and yield the best sequence possible. 
EXO/SAP is a common way to purify the PCR products before sequencing, the mixture 
is made out of equal amounts of exonuclease I (EXO) that remove the primers and 
shrimp alkaline phosphatase (SAP) that dephosphorylase the dNTPs to dNDPs and/or 
dNMPs.  
 
The sequencing method used in this project was thermal cycle sequencing which has two 
main advantages over the Chain termination method; double stranded DNA can be used 
as a template (1) and only a little amount of DNA is needed for sequencing and therefore 
no cloning is needed to succeed (2). In each reaction only one strand is copied because of 
the use of just one primer. In other ways this method is built on the same principals as the 
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chain termination method: a small amount of ddNTPs (dedeoxynucleotides) is added to 
the reaction, when ddNTP is incorporated into the growing strand of DNA the elongation 
process stops due to the lack of the 3’-hydroxyl-group needed to form the connection 
with the next nucleotide [Brown 2006]. 
 
Procedure 
1) Make the EXO/SAP mixture; calculate 1µl mixture pr sample (0,5µl EXO and 
0,5µl SAP for each sample) and 2 – 4µl excess mixture. This was done on ice. 
2) Add 1µl EXO/SAP to each sample while working on ice. 
3) Run the samples at the following program to remove primers and 
dephosphorylase dNTPs (a PCR machine was used for this): 37˚C for 1minute  
37˚C for 1-hour  85˚C for 15 minutes. 
4) Set up the sequencing reaction as in table 13, work on ice. 
 
 










BigDye 3.1 1µl 
Template (30-1200ng) 3-6µl 
BigDye sequencing buffer (5X) 2,5µl 
Primer (2 pmol/µl) 1,6µl 
MQH2O up to 20µl 
Total volume 20µl 
5) Prewarm the PCR machine to 95˚C and insert the samples, run a PCR using the 
following program: 
96˚C for 1 minute 
25 cycles: 
96˚C for 10 seconds 
50˚C for 5 seconds 
60˚C for 4 minutes 
Cool the samples at 4˚C until the samples are removed from the machine. 
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6) When the PCR were finished the markings on the samples were checked and 
refreshed if needed. Then the samples were delivered to the Sequencing Lab Unit 
where the samples would be precipitated for the terminator reaction. 
 
Analyzes of DNA sequences 
The DNA sequences were analyzed by using Chromas Lite and BioEdit. 
 
Procedure 
1) Every sequence was searched for N’s, which could be any of the four nucleotides. 
Each N was tried replaced with the correct nucleotide by checking which top 
beneath the N was the highest.  
2) When finished in Chromas every sequence was saved as a fas file so the edited 
sequences could be opened in BioEdit. 
3) In BioEdit each sequence from a reverse primer was reversed and complemented 
using the “the reverse complement” from the “Sequence” menu. 
4) The sequences belonging to the same primer pair was aligned using a local 
alignment allowing terminal gaps. 
5) The aligned sequences were then aligned with the appropriate given operons 
checking for mutations and orientation of the insert.  
6) The sequences were also checked for the CACC overhang and ATG start codon. 
7) When all the ends were checked the middle part of the pili genes were sequenced, 
checked and edited for N’s in Chromas and the reverse primer sequences were 
reversed and complemented in BioEdit. 
8) The sequences for each pili gene were put together aligning the partial sequences 
and making a consensus between each aligning. See figure 12, next page. 
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Figure 12- Putting together partial sequences to make a consensus sequence. The 
red areas are the overlapping sequences between the partial sequences. 
 
9) The approximate size of the gene product was calculated using the option “amino 
acid composition” under the sequence menu. 
 
Cloning with Gateway® Technology 
This was done by Invitrogens pENTR Directional TOPO® cloning Kit and E. coli 
Expression System with Gateway® Technology.  
 
The Gateway® technology cloning method contains three main steps; (1) TOPO® cloning 
of blunt ended PCR products into an pENTR TOPO vector to form an entry clone, (2) 
performing an LR recombination reaction between entry clone and a gateway ® 
destination vector to form an expression construct, and finally (3) introducing the 
expression construct into an appropriate host for expression and express the protein. 
[Snyder & Champness 2007,Invitrogens pENTR Directional TOPO® cloning Kit, E. coli 
Expression System with Gateway® Technology]. Figure 13 shows the principle behind 




Figure 13 - An overview of the Gateway technology. 1) Topo cloning of blunt ended PCR products 
into pENTER, an entry vector. 2) LR recombination of the PCR product into a destination vector, 
pDEST17. 3) Transformation of the destination vector into an appropriate expression host. 4) 
Expression of the gene of interest. 
 
Topo cloning relays on topoisomerase I from vaccinia viruses which has a strong 
sequence specificity and always makes a break next to the 3’T in the following 5bp 
sequence: 5’-(C/T)CCTTNNN-3’. Normally type I topoisomerase makes a single 
stranded break in one DNA strand, and while topoisomerase I stays attached to the 3’T, 
the other strand passes through the break to form or remove super coiling in the DNA 
molecule. But if the break is made within 10bp from the end the last part of the DNA 
falls apart leaving a 5’-overhang that can pair with a complementary 5’-overhang and 
topoisomerase will ligate the two molecules together [Snyder & Champness 2007].  
 
The LR recombination reaction between the attL flanked sequence in the entry clone and 
the attR destination vector creates an attB-containing expression clone. With the help 
from an enzyme mix containing the bacteriophage λ integrase and excisionase proteins 
mediates the reaction, and the E. coli integration host factor protein; this enzyme mix is 
called LR ClonaseTM II Enzyme Mix [Invitrogen LR Clonase manual]. 
 
In the pDEST17 vector the expression of the gene of interest is controlled by a strong 
bacteriophage T7 promoter that is recognized by the T7 RNA polymerase.  
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In BL21-AITM E. coli strain the T7 RNA polymerase is inserted into the araB locus of the 
araBAD operon making it possible to induce expression of the T7 RNA polymerase by 
the sugar L-arabinose, and repress the expression by glucose. By transforming the 
pDEST17 with the gene of interest into BL21-AI competent cells that supplies T7 RNA 
polymerase it is possible to express the protein encoded by the inserted gene of interest 
by adding L-arabinose to the culture, or repress the expression of the gene by adding 
glucose [Invitrogens E. coli expression system with Gateway technology manual]. 
 
Topo® Cloning to Entry Vector and Transforming into One 
Shot® Competent E. coli 
This was done by Invitrogens pENTR Directional TOPO® cloning Kit. 
 
Procedure 
1) The cloning reaction was mixed as in table 14. The molar ratio between the PCR 
product and vector should be 0,5:1 to 2:1 for the most effective cloning. The 
amount of PCR product was estimated by visualization in an agarose gel.  
 
Table 14 Cloning reaction mix 
Reagents Volume 
Fresh PCR product 0,5 – 4µl 
Salt solution 1µl 
Sterile water Add to final volume of 5µl 
TOPO® vector 1µl 
Final volume 6µl 
 
2) The reaction was gently mixed and incubated for 5 minutes in room temperature. 
After the incubation the cloning reaction was placed on ice. 
3) 2µl of the TOPO® cloning reaction was added into a vial of One Shot® chemically 
competent E. coli cells, and mixed gently (not by pipetting). 
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4) The competent cells with the cloning reaction were incubated on ice for 5 – 30 
minutes. 
5) The cells were heat-shocked for 30 seconds at 42˚C without shaking. The cells 
were immediately transferred to ice after the heat-shock. 
6) 250µl of room temperature S.O.C. medium was added to the cells. The tubes were 
capped tightly and shaken horizontally at 200 rpm in an incubation shaker for 1 
hour at 37˚C. 
7) 50µl were spread on one LB plate containing 50µg/ml kanamycin, and 150 µl 
were plated on another plate. The plates were incubated over night at 37˚C. 
8) Single colonies were picked for plasmid isolation. The cells were incubated over 
night at 37˚C in 10-15 ml LB medium containing 50µg/ml kanamycin, the tubes 
were shaking at 220rpm in an incubation shaker. 
 
LR- Recombination and Transforming Library Efficiency® 
DH5αTM Cells 
This was done with E. coli Expression System with Gateway® Technology from 




1) The contents in table 15 were mixed in 1,8ml eppendorf tubes in room 
temperature 
 
Table 15 - shows the concentrations of entry clone and destination vector in the LR-
recombination reaction.  
Component Sample Positive Control 
Entry clone (50-150 ng/ reaction) 1-7 µl - 
Destination vector (150 ng/µl if supplied 
by the kit)1)
1µl 1µl 
pENTRTM-gus (50ng/µl, positive control) - 2µl 
TE buffer, pH8,0 To 8µl 5µl (or to 8µl) 
In this project the destination vector had to be isolated from its host and the amount of destination 
vector is approximately 150ng/ reaction. 
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2) The LR ClonaseTM Enzyme Mix (supplied by the kit) was removed from the -
20˚C freezer and thawed on ice, this took approximately 2 minutes. 
3) The LR ClonaseTM Enzyme Mix was vortexed briefly twice, approximately 2 
seconds each time. 
4) 2µl ClonaseTM Enzyme Mix was added to each sample, the sample and clonase 
was mixed by pipetting up and down. The ClonaseTM Enzyme Mix was 
immediately returned to the -20˚C freezer after use. 
5) The reaction was incubated for 1 hour at 25˚C (room temperature). 
6) 1µl Proteinase K solution (supplied by the kit) was added to each reaction, and the 
reaction was incubated for 10 minutes at 37˚C. (Can be stored up to 1 week at  
-20˚C before transformation.) 
7) For each sample one tube of 100µl chemical competent DH5α E.coli cells were 
thawed on ice. 
8) To each tube of chemical competent DH5α E.coli cells, 2-5µl LR recombination 
reaction was added; this was gently mixed (not by pipetting up and down!). 
9) The cells were incubated on ice for 30 minutes on ice. 
10) The cells were heat-shocked at 42˚C for 30 seconds without shaking, after the 
heat-shock the cells were immediately put on ice. 
11) 450µl S.O.C. medium (supplied by the kit) with room temperature was added to 
the cells. 
12) The tubes were tightly caped and shaken at 200rpm in an incubation shaker for 1 
hour at 37˚C. 
13) For each reaction 20µl and 100µl were spread out on selective LB plates 
containing 100 µg/ml ampicillin and incubated over night at 37˚C. 
14) Cells were harvested for overnight cultures, plasmid purification and analyzes of 




Transforming BL21-AITM One Shot® Cells 
This was done by Invitrogens E. coli Expression System with Gateway Technology kit. 
 
Procedure 
1) For each transformation one vial of BL21-AITM One Shot® Cells was thawed on 
ice. 
2) 5-10ng DNA in a volume of 1-5µl was added to each vial of BL21-AITM One 
Shot® Cells, and mixed by gentle tapping. 
3) The transformation mixture was incubated on ice for 30 minutes 
4) The cells were heat shocked at 42ºC for 30 seconds, and the vials were 
immediately transferred to ice. 
5) 250µl room temperate S.O.C. medium were added to the cells. 
6) The tubes were tightly capped and incubated in 37ºC for 30 minutes, shaking at 
200 rpm in an incubation shaker. 
7) 20µl and 100µl were spread out on two different pre-warmed selective plates, 
containing 100 µg/ml ampicillin, and incubated over night at 37ºC. 
 
Protein Isolation and Detection 
The gene of interest is inserted in the T7 RNA polymerase, which is induced by L-
arabinose, and repressed by glucose that acts as a repressor. The expression can therefore 
simply be regulated by the addition of L-arabinose to activate transcription, or the 
addition of glucose to repress the transcription [E. coli expression System with Gateway 
Technology]. 
 
Western blotting is useful for the identification and quantification of specific proteins, it 
relays on the transfer of electrophoretically separated proteins from the gel to a solid 
support, e.g. a membrane. To detect the proteins the membrane is probed with antibodies 




Antibodies are immunoglobulin’s, and can be made to detect specific proteins. The 
antibody recognizes and binds to the antigens epitope that is a 5 to 8 amino acid long 
domain, normally located on the protein surface. There are two different types of 
epitopes; continuous, which mean that they are on the same peptide, or discontinuous, 
which mean that the amino acids that make up the epitope is brought together by the three 
dimensional structure. Antibodies might bind to fragments, denatured fragments or the 
native protein, depending on the antibody it self and the type of epitope it recognizes 
[Novus Biological antibody guide]. 
 
There are 5 classes of antibodies; IgM, IgD, IgA, IgG and IgE, all of these classes share 
the same basic structure: Two identical heavy polypeptide chains (440 amino acids) and 
two identical light polypeptide chains (220 amino acids) that are held together by both 
covalent and non-covalent disulfide bonds that form a symmetrical Y structure with 
identical halves see figure 14, the number and type of disulfide bonds varies between the 
classes. The antigen binding sites are located on the top ends of the Y structure, see figure 




Figure 14- Blotting and detection with antibodies 
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His-tags are normally composed of six histidine residues and are the simples of all tags 
used for protein purification. The his-tag is most often located on the N or C terminus of 
the protein where it is less chance that it will influence the protein function. If a part of 
the protein is known to be non-essential for the function of the protein, the his-tag can be 
located in this part [Reece 2004]. 
 
His-tagged proteins can be easily purified in a one step purification. The imidazole rings 
in the histidines binds strongly metal ions like Ni2+, this binding is non-covalent. By 
adding increasing concentrations of imidazole to the column will elute the his-tagged 




This was done by Invitrogens E. coli Expression System with Gateway Technology kit. 
 
Procedure 
1) 4 transform ants were selected from the “BL21-AITM One Shot® Transformation” 
procedure previously described.  
2) The transformants were cultured in LB medium containing 100µg/ml ampicillin at 
37˚C with shaking until the cultures reached an OD600 between 0,6 and 1,0. These 
cultures were used to inoculate fresh LB medium containing 100µg/ml ampicillin 
to an OD600 between 0,05 and 0,1 (this was approximately a 1:20 dilution of the 
initial culture). The volume of fresh culture were big enough to take samples for 
measurement of OD600 until it reached approximately 0,4, split the cultures in 
two, and take up to 5 time point samples of 500µl each.  
3) The cultures were grown until mid-log phase, OD600 ~0,4, and split into two 
cultures. 
4) To induce the culture L-arabinose was added to one of the cultures to a final 
concentration of 0,2%. The other culture was left uninduced. 
5) 500µl aliquot was removed from each culture.  
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6) The aliquot was centrifuged for 30 seconds at maximum speed to pellet the cells, 
the supernatant was discarded and the pellets were frozen at -20˚C. These pellets 
were the time zero samples. 
7) The rest of the cultures were incubated at 37˚C with shaking. 
8) Time points were taken every hour for 4 hours, 500µl aliquot each time and 
treated as in step 6. 
 
Preparing Samples for Water Soluble/ Insoluble Protein 
This was done by Invitrogens pENTR Directional TOPO® cloning Kit. 
 
Procedure 
1) Lysis buffer were made. 
2) Each pellet from the “Pilot expression” procedure were thawed and resuspended 
in 500µl of lysisbuffer. 
3) The samples were frozen in dry ice; this was done by setting the samples in the 
ice and pouring ethanol over. This was repeated 3 times. 
4) The samples were centrifuged at maximum speed for 1 minute at 4˚C to pellet the 
water insoluble proteins, and the supernatant were transferred to a new eppendorf 
tube and stored on ice. 
5) 5 µl 2X SDS-PAGE sample buffer, 7 µl water and 8 µl supernatant were mixed 
and boiled for 5 minutes. 
6) The pellets from step 4) were resuspended in 500µl 1X SDS-PAGE sample buffer 
and 20µl were taken out and boiled for 5 minutes. 
7) 10µl of the supernatant sample and 5µl of the pellet sample were loaded onto an 





1) A NuPAGE 4% -12% Bis-Tris gel was taken out of the bag, the gel cassette was 
washed with deionised water and the tape at the bottom was removed. 
2) The comb was carefully removed from the cassette and wells were washed with 
1X NuPAGE running buffer. The cassette was hold up-side down to remove 
excess buffer. This was repeated twice. 
3) The outer chamber was filled with NuPAGE Mes running buffer 1X. 
4) The inner chamber was filled with NuPAGE Mes running buffer 1X and 500µl 
antioxidant.  
5) The gels were placed in the minicell, the wells facing the inner chamber. The 
dummy gel was only used when one gel was used. 
6) 10µl of each pellet sample, 20µl of each supernatant sample, and 3µl 
MagicMarker Molecular weight standard were loaded on the gel. The molecular 
weight standard was loaded first, followed by uninduced samples and induced 
samples at the end. 




1) After SDS-Page electrophoresis (described above) the gel was fixed for 1 hour in 
fixing solution for NuPAGE® Novex gels. 
2) The fixing solution was decanted and the gel was washed 2x 10 minutes in 100ml 
deionised water, the water was disposed of between the to washings. 
3) The gel was covered in ready to use solution and InVisionTM His-tag In-gel Stain 
and incubated for 1 hour. 
4) The stain was disposed and the gel was washed in 20mM phosphate buffer, pH7,8  





1) SDS –Page electrophoresis. 
2) 1X blotting buffer and 1X TBST was made during the gel run. 
3) 5 blotting pads soaked in blotting buffer in a container. They had to be completely 
wet and free of air. 
4) Two pieces of membrane were cut to the approximately same size as the gel, the 
right corner was cut off and the side that was going to lie against the gel was 
marked with a soft pencil. The membranes were put in separate holders 
containing blotting buffer while the SDS-page electrophoresis ran. 
5) Four pieces of filter paper was cut to the same size as the blotting pads. 
6) When the gel was finished the plates were carefully separated, the plate on top 
was removed, and the gel was on the bottom plate. 
7) The wells and the gel foot were removed with a gel knife, and a filter paper 
moisturised in blotting buffer was placed on top of the gel. Air bubbles were 
removed by rolling a glass rod over. 
8) The plate with the gel and filter paper was laid up side down in the hand, and the 
gel knife was used to carefully remove the last plate. 
9) The wet membrane was put on the gel with the marked side down. And a filter 
paper moisturised in blotting buffer was placed on top of the membrane. 
10) Two blotting pads was laid in the cathode core of the blotting chamber, the 
sandwich containing the gel and the membrane was put on top of the blotting 
pads, membrane side up. One blotting pad was put on top of the sandwich. 
11)  Steps 6-10 were repeated for the second gel. 
12) The second gel sandwich was put on top of the blotting pad, membrane side up, 
and the last two blotting pads was put on top and the anode core was placed on 
top to close the blotting chamber. See figure 15 (next page) for the build up. 
13) The blotting chamber was placed in the blotting module, while pressing it 
together. 
14) The blotting chamber was filled with 1X blotting buffer, and the blotting 
module/outer chamber was filled with deionised water. 
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15) Blotting was run on 30V for 1 hour. 
 
 
Figure 15 - The set up for western blotting with two gels 
 
Immunodetection with anti-his antibodies 
This was done using QIAexpress Detection and Assay handbook 10/2002 protocol 7, 




The membranes were treated in different containers 
1) The membranes were washed for 10 minutes in TBS buffer at room temperature. 
2) The membranes were incubated in blocking buffer over night at 4ºC. 
3) The membranes were washed twice for 10 minutes in TBS-Tween/Triton buffer at 
room temperature. 
4) The membranes were washed for 10 minutes in TBS buffer at room temperature. 
5) The membranes were incubated in Anti-His HRP Conjugate solution for 1 hour at 
room temperature. 
6) The membranes were washed twice for 10 minutes in TBS-Tween/Triton buffer at 
room temperature. 
7) Each membrane was incubated for 1 minute in 3,5ml of each bottle Super signal 
West Pico Chemiluminicent Substrate. And air-dried. 
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8) The dry membranes were taped in a cassette and a transparent was taped over the 
membranes. 
9) In the dark (only red light on): Two layers of Chemiluminicent film were taped 
over the membranes. The first film was developed after 5 minutes, the next after 1 
hour, if no signals new film were taped on, the third was developed after two 
hours and the last was developed the next morning. 
 
Screening for Pili 1:44 and Pili 1:48 
93 isolates were screened for pili 1:44 and 1:48, the PCR programs and primers used 
were those in table 12 for pili 1:44 and pili 1:48 products. The positive control was E. 
faecium DO, the negative control was S. epidermis and the water was used as mastermix 
control. E-Gel® 96 Gels was used. 
 
Procedure 
1) Distilled water was added to the samples to a final volume of 22µl. 
2) The Mother E-BaseTM was plugged into an electrical outlet, and the pwr/prg 
(power/program) button was pressed and released to select program EG. 
3) The gel was removed from the package and the comb was removed from the gel. 
4) The gel was slided into the Mother E-BaseTM.  
5) 20µl sample was loaded into each well. The loading had do be done within 30 
minutes after the gel was removed from the package. 
6) E-Gel® Low range quantitative DNA marker was loaded into the marker wells. 
7) 20µl sample buffer was loaded into the empty wells. 
8) The pwr/pgr button was pressed and released to start the run. After about 12 
minutes the gel is finished, the pwr/pgr button was pressed and released again to 
stop the beeping. 




Estimating p-value by Using χ2-test 
The χ2-test is used to check for correlation between two variables. In this sort of test the 
0-hypothesis will always be “no correlation”, and the hypothesis to be tested will be if 
there is a correlation, and the decision to be made is whether or not the 0-hypothesis is 
true. When the χ2 is large, there is a correlation and the 0-hypothesis is rejected, the 
opposite is true when the χ2 is small [Ringdal 2001]. 
 
There are two types of mistakes that can be made in a χ2-test. One is when a true 0-
hypothesis is rejected, it is called a type I fail, and the chance of doing this mistake is set 
by the α-value. Normally α=0,05, which mean that the researcher is prepared to accept a 
5 % chance for the results to be wrong or random [Ringdal 2001].  
 
The other mistake that can be made is a β-mistake, this occurs when a wrong 0-
hypothesis are being kept. This mistake is strongly connected to the α-value, the lower 
this value is the bigger the chance of making the β-mistake is [Ringdal 2001]. 
 
The number of “test objects” also affects the outcome of a χ2-test. If it is a large amount 
of samples tested, a small difference or a weak correlation can lead to a rejection of the 0-
hypothesis. In a smaller collection of samples small differences or weak correlations will 
not have the same effect. This means that it is easier to reject the 0-hypothesis in a large 
collection, than in a smaller one, providing that all other factors are equal [Ringdal 2001]. 
 
The “degree of freedom” (df) were calculated by taking the number of columns minus 
one and multiplying it with the number of rows minus one, for this example: df = (2-
1)x(2-1) = 1 [Griffiths et al. 2002]. 
 
The α value was set to α=0,05, which has become the standard α value [Ringdal 2001, 
Jekel et al. 2001]. 
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E was calculated for all four possibilities using the formula (row total/study total)(column 
total/study total) x study total. Figure 16 shows an example of how a grid could look like, 
the estimated E is in parentheses. 
  pili non-pili Totals 
Human 33 (31) 44 (46) 77
Non Human 4 (6) 12 (10) 16
Totals 37 56 93
 Figure16- Example of a grid with 4 variables used in the estimation of E. The numbers in the white 
cells is the observed number, and the numbers in parentheses are the estimated E. 
 
The statically significance was estimated: χ2= Σ(O-E)-0,5)2/E, were O is the observed 
number in a class and E is the expected number of the same class. To correct for 
continuity in the χ2 test, 0,5 was subtracted from the sum of (O-E), this will not make a 




For all PCR protocols: E. faecium DO was used as positive template, Staphylococcus 
epidermis or E. faecium BM 4105-RF were used as negative templates, and water was 
used as master mix control. 
 
PCR Optimalization 
The PCR protocols were optimized using E. faecium DO as positive template, S. 
epidermis as negative template, and H2O as mastermix control for the primers marked in 
table 12. The Optimalization was done because of unspecific primer binding resulting in 
positive products in the negative control, and in some cases more than one DNA band in 
electrophoresis. Figure 17 shows one example of Optimalization results. The marked 
PCR programs in table 12 shows the annealing temperatures based on the Optimalization. 
The optimal annealing temperature was when the positive template was positive and the 
negative template was negative. 
 
 
          A   A    A  B    B  B  C    C  C  D  D   D  E    E   E   F    F   F 
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Figure 17- Optimalization results of the PCR programmes. Lane L is 1kb+ molecular weight 
standard, lanes: 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31 and 34 were mastermix controls (H2O). Lanes: 2, 
5, 8, 11, 14, 17, 20, 23, 26, 29, 32 and 35 contains the negative template, and wells: 3, 6, 9, 12, 15, 18, 
21, 24, 27, 30, 33 and 36 contains the positive template. Block A) 54ºC, B) 55,1ºC, C) 57,4ºC, D) 
61,2ºC, E) 64,2ºC, F) 65,8ºC. 2:44 and 2:48 refers to the primer pairs listed in table 12. 
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The PCR results showed confirmed the E. faecium DO to be positive for the pili genes, 
after optimalization S. epidermis was negative for all pili genes.  
 
E. faecium DO, E. faecium 64/3 and E. faecium BM 4105-RF were tested for both operon 
44 and 48. In operon 44 E. faecium DO was positive for all genes, E. faecium 64/3 was 
positive for pili 1:44 and pili 3:44, and E. faecium BM 4105-RF was negative for all 
except pili 2:44. In operon 48 E. faecium DO was positive for all genes, E. faecium 64/3 
was positive for pili 1:48, 2:48 and pili 3:48, and E. faecium BM 4105-RF was negative 
for all. 
 
Cloning into pENTR 
The PCR product of C3:44R1 and C3:48R1 were ligated into the pENTR vector, and 
transformed into OneShot competent cells. Confirmation of insert was done by PCR. 
 
Both C3:48 and C3:44 were successfully cloned into the pENTRTM Topo vector by 
Topo® cloning and transformed into One Shot® Competent E. coli cells, C3:44 had 27 
transformants, and C3:48 had 40 transformants.10 transformants from each 
transformation were checked by PCR with C3:44M and C3:48M1 primers (see table12  
for primer pairs) to screen for the proper insert. Figure 18 shows the result from such a 
PCR. Clones in lanes 10-13 and 22-26 had the proper insert with expected size, and 
plasmids from clones 8-10 in lanes 11-13 and 18-20 in lanes 18-20 were purified for 
recombination with pDEST17 vector. 
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Figure 18- Amplification of inserts in the pENTR vector. Lane L is the 1 kb+ molecular weight 
standard. Lanes 1 and 14 are the mastermix control, 2 and 15 are the positive template (DO), 3 and 
16 are the negative template. Pili 3:44M primers were used to check C3:44 transformants; lanes 4-13 
is C3:44 transformants, lanes 10-13 is C3:44 transformants with insert.  Pili C3:48M1 primers were 




Plasmid Purification for Recombination into pDEST17 
E.Z.N.A. Plasmid Miniprep protocol II was used for purification of for high copy number 
plasmids (pENTR vector), the NanoDrop was used to check the quality and amount of 
purified plasmid. 
 
Table 15 (next page) shows the plasmid purification results for the clones used in later 
experiments. A 260/280 ratio greater than 1,8 indicates that the nucleic acid purity is 
greater than 90%. The concentration of plasmid pSI20C was not as high as expected, but 
it was high enough for later use. The concentration of plasmid A was as expected. 1,5 µl 
pSI20C was used for recombination with pDEST17, and 2 µl A was used for 
recombination with pDEST17, to fill the protocols demand of 50-150ng entry clone in 1-
7µl sample. 
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Table 15- Quantity and purity of purified plasmids. 
Plasmid ng/µl 260/2801 H/L2 44/483 Further use 
pSI 20C 29,75 1,75 H 48
Transformation and LR 
recombination  
A 49,18 1,99 H 44
Transformation and LR 
recombination  
1 a 260/280 ratio greater than 1,8 indicates a nucleic acid purity greater than 90% 
2 H = High copy number plasmids, L= Low copy number plasmids 
3 44 = pili C3:44 clones, 48= pili C3:48 clones 
 
Sequencing 
PCR for sequencing was done by cycle sequencing programme where the template was 
PCR products or plasmid, and only one primer was used. The sequencing lab precipitated 
and used a terminator reaction for obtaining the sequence. Sequencing was done to 
confirm right orientation of the inserts, confirm that the length and sequence was the 
same as the operon 44 and 48. Sequencing was done from PCR products, and figure 19 
shows the results from such a PCR. Products from E. faecium DO, wells 2, 6, 10, 14 and 
18 were sequenced. The products were judged, based on figure 19, to have the expected 
size. 
 
L  1    2    3   4   5    6   7   8   9    10  11  12  L






Figure 19- PCR products for sequencing. Lane L contain the 1 kb+ molecular weight standard. 
Lanes: 1, 5, 9, 13 and 17 contain the mastermix control. Lanes: 2, 6, 10, 14 and 18 contain the positive 
template. Lanes: 3, 7, 11, 15 and 19 contain the negative template (E. faecium64/3). Lanes: 4, 8, 12, 16 
and 20 is the E. faecium BM 4105-RF. 1:48 and 2:48, 3:48, 2:44 and 3:44, refers to the primer pairs 
listed in table12. 
 
 71
All primers were used for sequencing and the size of the PCR products in table 16 are 
based on the sequences obtained. The PCR results showed that there were some 
differences between the expected size and the obtained size from sequencing, these 
differences was mainly in the ends, and some gaps were registered.  
 
The difference between 10 PCR products and the expected size differed only by few 
nucleotides, less than 10. 5 PCR products differed with more than 10 nucleotides from 
the expected size, with pili C3:48R2 as the one with the biggest difference, this sequence 
had one strand successfully sequenced. One PCR product, pili 3:44 3’, had the exact 
same size as expected. 
 
Table 16- Size of PCR sequences. 
Product Primers (Forward/Reverse) Expected size (bp) Size (bp) obtained 
from sequencing 
Pili 1:441 Pili 1:44F/ Pili 1:44R 370 372 
Pili 2:441 Pili 2:44F/ Pili 2:44R 497 500 
Pili 3:441 Pili 3:44F/ Pili 3:44R 420 421 
Pili C3:44R11 Pili C3:44F/ Pili C3:44R1 1682 1686  
Pili C3:44R21 Pili C3:44F/ Pili C3:44R2 1674 1610 
Pili C3:44 5' M13F/ Pili 3:44RL 720 739 
Pili C3:44M Pili 3:44FM/ Pili 3:44RM 756 755 
Pili C3:44 3' Pili 3:44 FR/ M13 R 699 699 
Pili 1:481 Pili 1:48F/ Pili 1:48R 523 522 
Pili 2:481 Pili 2:48F/ Pili 2:48R 418 409 
Pili 3:481 Pili 3:48F/ Pili 3:48R 323 322 
Pili C3:48R11 Pili C3:48F/ Pili C3:48R1 1857 1826 
Pili C3:48R21 Pili C3:48F/ Pili C3:48R2 1854 1222 
Pili C3:48 5' M13F/ Pili 3:48RL 650 497 
Pili C3:48M1 Pili 3:48FM/ Pili 3:48RM 699 693 
Pili C3:48M2 Pili 3:48FR/ Pili 3:48R 722 724 
Pili C3:48 3' Pili 3:48F/ M13R 746 735 
1) Optimized PCR for these primers. 
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C3:44 3’, C3:44 5’, C3:48 3’ and C3:48 5’ were used to sequence the ends and confirm 
the orientation, the primers for these products are found in table 12. By sequencing 
C3:44M, C3:48M1 and C3:48M2 using the primers noted in table 12, the middle part of 
the sequences of the C3:44 and C3:48 genes. The full sequences were obtained by 
making a consensus of the sequences from the ends and the middle. 
 
The sequencing showed that the pili C3:44 was almost identical to operon 44, that the 
right part of the genome had been amplified, and that the insert was inserted correct for 
further work. The estimated size of the protein encoded by the C3:44 sequence was 
approximately 136 kDa. The difference between operon 44 and the obtained sequence 
was the 5’C in the CACC in the beginning of the sequence. 
 
The sequence for C3:48 is almost identical to operon 48, the difference was the ACC in 
the CACC. The sequence confirmed the orientation of the insert, and that the right part of 
the genome had been amplified. The estimated size of the protein encoded by the C3:48 
sequence was approximately174 kDa. 
 
The sequences obtained are found in appendix A, were C3:44 are aligned with operon 44, 
and C3:48 are aligned with operon 48. Primers used for cloning are written in blue, 
primers used for sequencing are written in green, and red markings indicate the 
differences between the operons and the obtained sequences. 
 
Cloning into pDEST17 
The cloning of the insert into pDEST17 vector was done by recombination between the 
pENTR and pDEST vector followed by transformation into DH5α chemical competent 




C3:44 were successfully recombined into the pDEST17 vector and transformed into 
DH5α competent E. coli cells for maintaining of the plasmid, the transformation resulted 
in 23 transformants. The presence of insert was confirmed in 2 out of 7 tested clones by 
internal primers, se figure 20. Lanes 10 and 11 in figure 20 shows C3:44 transformants 
with inserts, and plasmid was purified from these clones for transformation into BL21-AI 
cells for expression. 
 
     L      3     5      7      9     11    13   15     17   19    21    L 
         2     4     6      8      10    12   14   16      18   20   22 
850 bp
 
Figure 20- PCR amplification of inserts in the pDEST17 vector. Lanes L contains the 1kb+ molecular 
weight standard. Lanes 2 and 13 contain mastermix controls (H2O), 3 and 14 contain negative 
controls, 4 and 15 contain positive controls. Lanes 5-11 contain C3:44 transformants, lanes 10 and 11 
show transformants with insert, primers 3:44RM/FM were used.  Lanes 16-22 contain C3:48 
transformants, no clones with insert was confirmed, primers 3:48RM/FM were used, see table 12. 
 
C3:48 clones gave colonies when transformed into DH5α competent E. coli cells, but 
PCR with internal primers did not confirm a successful recombination into pDEST17, no 
inserts were observed, se figure 20. After two attempts, the cloning of C3:48 into pDEST 
was terminated. 
 
Purification of Plasmids for Protein Expression 
Plasmid purification was done with the E.Z.N.A. Plasmid Miniprep protocol I for low 
copy number (pDEST vector). NanoDrop was used to check the quality and amount of 
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purified plasmid. The pDEST17 vector had to be purified; the same protocol was used for 
this purification. 
 
Table 17 shows the plasmid purification results for the clones used in later experiments. 
A 260/280 ratio greater than 1,8 indicates that the nucleic acid purity is greater than 90%. 
A6 had to be diluted 1:1 with water, to obtain 5-10 ng DNA in 1-5 µl sample as required 
in the protocol, before transformation into BL21-AI cells and expressed.  
 
Table 17- Quantity and purity of the purified plasmids 
Plasmid ng/µl 260/2801 H/L2 44/483 Further use 
pDEST 
17 19,03 2,22 L - Vector 
A6 13,47 1,94 L 44 Transformation and expression 
20C1 10,7 1,94 L 48 Not used 
1 a 260/280 ratio greater than 1,8 indicates a nucleic acid purity greater than 90% 
2 H = High copy number plasmids, L= Low copy number plasmids 
3 44 = pili C3:44 clones, 48= pili C3:48 clones 
 
 
Expression of C3:44  
The pDEST17 with the insert was transformed into BL21-AITM competent cells for 
expression. The cells were lysed using a protocol to separate water soluble and insoluble 
proteins by centrifugation at 4˚C, and a western blot was performed to check if the 
protein was in the water soluble or insoluble fraction. Detection was done by 
chemiluminiscense. InVision staining was also performed to check the solubility of the 
protein, but this method failed. 
 
Only pili C3:44 was cloned and expressed, the expression showed that the protein was 
water insoluble. Figure 21 shows an example of expression results. The protein seems to 
be approximately 100kDa, which is less than the estimated 135,5kDa. All three clones 
tested in this experiment expressed the pili protein in the pellet fraction, containing water 
insoluble proteins, from the induced cells.  
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The first western blot showed that more and more protein was produced for each time 
sample, just as one would expect, and the result showed that after two hours the induced 
cells had produced enough protein for detection and purification. After 3 hours a lot of 










Figure 21- Western blot of a SDS-PAGE. The left side is the lysate/supernatant, the right side: Lane 
1-3 contains the uninduced cells; lane 4-6 contains the induced cultures. The Magic Marker 
molecular weight standard is in the two lanes with several bands. 
 
Prevalence of Pili Genes 
The prevalence of pili loci were investigated by amplification of one selected region in 
each locus, 1:44 in operon 44 and 1:48 in operon 48. The collection of isolates was 
originally designed to check for VREfm [unpublished], and the same 96 well setup is 
used in this thesis. 
 
The screening of 93 isolates was performed running two PCRs with pili 1:44 and pili 
1:48 primers, the programs used are in table 12. After the PCR an E-gel was run to check 
if the isolates were positive or negative, no sizes were checked.  
 




The results in table 18 shows that a total of 73 isolates were positive for pili, 67 (92%)of 
these were positive for 1:44, 37 (51%) were positive for 1:48, while 31 (42%) were 
positive for both. This gave a p-value of 0,05, and there is a correlation between the two 
genes. 
 




















1a TUH 44-39 + + 5a TUH 32-79 - - 9a TUH N1-90 + + 
1b TUH 44-29 + + 5b TUH 32-80 - + 9b TUH N2-1 + - 
1c TUH 44-34 + - 5c TUH 340 + + 9c TUH N2-26 - - 
1d TUH 7-57 + + 5d TUH 4-15 + + 9d TUH N2-78 - - 
1e TUH 7-58 + - 5e TUH 4-21 + - 9e TUH N2-85 - - 
1f TUH 41-64 - + 5f TUH 4-22 + - 9f TUH S1-102 - - 
1g TUH 12-1 - - 5g TUH 4-41 - - 9g TUH S1-28 + - 
1h TUH 12-16 - + 5h TUH 4-65 + - 9h TUH S1-7 + + 
2a TUH 12-4 + + 6a TUH 44-23 + - 10a TUH S1-95 + + 
2b TUH 2-18 + + 6b TUH 44-31 + - 10b K8-42 + + 
2c TUH 2-19 + - 6c TUH 44-40 + - 10c K8-43 + + 
2d TUH 2-21 + + 6d TUH 45-12 + - 10d K8-45 + + 
2e TUH 2-8 + + 6e TUH 45-22 + - 10e K9-26 + + 
2f TUH 32-56 + - 6f TUH 45-3 + - 10f K9-27 + + 
2g TUH 32-61 - - 6g TUH 45-5 + - 10g K9-28 + + 
2h TUH 32-62 - + 6h TUH 44-52 - - 10h K9-72 - - 
3a TUH 32-63 - - 7a TUH 44-50 + - 11a K8-50 + + 
3b TUH 32-64 + - 7b TUH 44-42 + - 11b TUH 2-40 + + 
3c TUH 32-65 + - 7c TUH 44-47 + - 11c TUH 2-13 + + 
3d TUH 32-66 + - 7d TUH 45-35 + - 11d TUH 7-56 + + 
3e TUH 32-67 - + 7e TUH 45-25 - - 11e K8-61 - - 
3f TUH 32-68 + + 7f TUH 45-30 - - 11f K8-62 + + 
3g TUH 32-69 + + 7g TUH 7-15 + - 11g K8-64 + - 
3h TUH 32-70 + + 7h TUH 7-55 - - 11h K8-74 - - 
4a TUH 32-71 + - 8a TUH D2-34 + - 12a K8-69 - + 
4b TUH 32-72 + + 8b TUH D2-6 + - 12b K8-68 - - 
4c TUH 32-73 + - 8c TUH D2-69 + - 12c K9-10 - - 
4d TUH 32-74 + - 8d TUH D2-91 + - 12d K18-79 - + 
4e TUH 32-75 + + 8e TUH I1-82 + - 12e 41-73 - - 
4f TUH 32-76 + - 8f TUH N1-42 + + 12f Control - + 
4g TUH 32-77 + + 8g TUH N1-59 + - 12g Control + - 
4h TUH 32-78 - - 8h TUH N1-80 + - 12h Control - - 
1) ”-” is negative, ”+” is positive 
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Table 22 and figure 19 shows the results for screening for pili 1:44. The 67 distinct bands 
show the location of the positive isolates. 
 
Figure 22 - 1:44 screening, distinct bands between wells indicate positive isolates. The M indicates 
the lane of wells with the molecular marker. 
 
The p-values for pili 1:44 was above the α=0,05 for most of the χ2- tests. There were a 
correlation between pili 1:44 and the hospital, for the hospital survey isolates with a p-
value of 0,005, and a p-value of 0,05 for the hospital outbreaks isolates. There was also a 
correlation with isolates taken from other animal sources than faeces. 
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Table 19- The screening results from pili 1:44 
Pili 1:44   Total Positive % of types p-value
Total Humans and animals Isolates 93 67 72 - 
Humans Sample source Human 77 55 71 0,1 
  Origin Community Survey 11 7 64 0,5 
    Hospital Survey 7 1 14 0,005 
    Outbreak 5 5 100 0,1 
    Hospital outbreak 7 7 100 0,05 
    Clinical 44 32 73 0,5 
    Other 3 3 100 0,5 
  Isolation site/sample type Faeces 35 22 63 0,1 
   Blood 17 14 82 0,1 
   Urine 13 10 77 0,5 
   Other 10 5 50 0,5 
   From to sites 2 2 100 0,1 
  Van Type VanA and VanB 46 33 72 0,9 
      VanA  37 26 70 0,9 
      VanB 9 7 78 0,5 
   None 31 18 58 - 
  Geographical origin USA 8 6 75 0,5 
   Europe 68 48 71 0,5 
       Scandinavia 48 36 75 0,1 
          Norway 38 26 68 0,9 
    Other 1 1 100 0,1 
Animals Sample source Animals 14 11 79 0,5 
  Epidemiology Community survey 12 11 92 0,01 
    Other 2 0 0 - 
  Sample type Faeces 12 9 75 0,1 
    Other 2 2 100 0,005 
  Van Type VanA and B 9 7 78 0,5 
       VanA  9 7 78 0,5 
       VanB 0 0 0 - 
    None 5 4 80 - 




The 37 distinct bands in figure 23 shows the location of the isolates positive for pili 1:48 
in the screening. 
 
 
Figure 23- Screening for pili 1:48, a distinct band between wells indicates positive isolates. The M 
indicates the lane of wells with the molecular marker. 
 
The results in table 20 shows that there are correlation between pili 1:48 and blood (p 
=0,025), vancomycin resistance (p=0,01), more concrete vanA (p=0,005), and animals 
(p=0,025), and for these tests the 0-hypothesis is rejected. For the other tests there were 




Table 20- The screening results from pili 1:48 
Pili 1:48   Total Positive % of types p-value 
Total Humans and animals Isolates 93 37 40 - 
Humans Sample source Human 77 33 43 0,5 
  Origin Community Survey 11 4 36 0,5 
    Hospital Survey 7 2 29 0,5 
    Outbreak 5 3 60 0,5 
    Hospital outbreak 7 3 43 0,5 
    Clinical 44 20 45 0,5 
    Other 3 1 33 0,5 
  Isolation site/sample typeFaeces 35 18 51 0,1 
    Blood 17 3 18 0,025 
    Urine 13 5 38 0,5 
    Other 10 5 50 0,5 
    From to sites 2 2 100 0,5 
             
  Van Type VanA and VanB 46 25 54 0,01 
       VanA  37 22 59 0,005 
       VanB 9 3 33 0,5 
    Non vanA and VanB 31   0 - 
  Geographical origin USA 8 3 38 0,5 
    Europe 68 30 44 0,5 
       Scandinavia 48 21 44 0,9 
          Norway 38 18 47 0,5 
    Other 1 1 100 0,1 
Animals Sample source Animals 14 2 14 0,025 
  Epidemiology Community survey 12 2 17 0,1 
    Other 2 0 0 0,1 
  Sample type Faeces 12 2 17 0,1 
    Other 2 0 0 0,1 
  Van Type VanA and B 9 1 11 0,5 
       VanA  9 1 11 0,5 
       VanB 0 0 0 - 
    Non VanA and VanB 5 1 20 - 





The results showed that the PCR tools designed worked as planned for the primers.  
E. faecium DO was, as expected, positive for all pili genes. The results indicates that E. 
faecium BM 4105-RF might be negative for all loci tested for and could have been used 
as a negative control, while E. faecium 64/3 is positive for all, but pili 2:44. 
 
PCR Optimalization 
In E. faecium 64/3 strain every pili sequences except 2:44 were found, and in the E. 
faecium BM 4105-RF strain only 2:44 were found, this could indicate that the samples 
had been switched, but it was the same in every PCR run. Unspecific primer annealing is 
probably not the cause of these odd results, it was because of unspecific binding that the 
PCR programs had to be optimized, and the problem was solved after optimalization. 
 
Even though E. faecium BM 4105-RF strain has tested positive for only 2:44, there is 
reason to believe that this strain really is negative for the pili genes, and could be used as 
a negative control. 
 
Cloning into pENTR 
Both sequences were confirmed in the pENTR vector by PCR, and pili C3:44 was 
confirmed in the pDEST17 vector with the same method. The number of transformants 
were low, this could be due to the DNA:vector ratio not being optimal, or because the 
treatment of the competent cells were too harsh. 
 
Plasmid Purification for Recombination into pDEST17 
The amount of purified plasmids was lower than the lowest amount expected for the high 
copy number plasmid pSI20C. This can be because of poor cell lysis due to bad 
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dispersion of the cells prior to the addition of Solution II or to short incubation in 
Solution II (E.Z.N.A plasmid Miniprep kit I & II manual). NanoDrop was used for 
quantification of the plasmid, this method is not an accurate method, it gives an idea of 
the concentration, and the concentration of the purified plasmids was probably higher 
than the estimated concentration. NanoDrop also register the amount of contamination by 
proteins, so the nucleic acid purity of the sample tested can be checked, this sort of 
contamination would affect the DNA concentration. The results from NanoDrop indicates 
that there is a low contamination of proteins. 
 
The plasmid purity is not checked, the method does not differentiate between plasmid 
DNA and other DNA molecules, such as fragments. In some cases the NanoDrop gave a 
negative concentration of nucleic acid, and the blank control had to be measured to reset 
the control the samples were measured against. This should probably have been done 
between each sample, just to be sure. 
 
Alternatively the DNA concentration could be measured by running an EtBr agarose gel 
electrophoresis, where one lane contains DNA with known concentration. Using this 
method expose the presence of other DNA molecules, but it would not say anything 
about protein contamination. 
 
The concentration results from NanoDrop were used to estimate the volume of plasmid 
that had to be used to reach the recommended amount for transformation and 
recombination, and this could be a reason for transformation, and maybe recombination, 
failure. The amount and purity were important factors when the plasmids used for further 
use were selected. 
 
Sequencing 
Most sequences obtained had different length than the expected sequence length; this is 
due to the terminal N’s that had too weak signals to be read and because of that was 
deleted to obtain a better alignment between the two strands. Most sequences had some 
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internal gaps, this was probably because of misreading of the N’s in the sequence, or 
misreading of peaks that might have been background, or the nucleotide had been placed 
a bit too late or early compared to the peak. 
 
Sequences used for sequencing C3:44 and C3:48 did not have the expected sequence 
length, but when the sequences were put together the lengths were as expected. 
 
In addition to this not all sequences had a successful sequencing of the two strands, and 
therefore some lengths are based on only one strand. This was especially a problem for 
pili C3:48 R2, which had a long expected length and only one primer gave a sequence, 
when the sequences are long it is important to obtain sequences from both strands to get 
the best sequence. 
 
When the gaps are spread the reading frame will be shifted after each gap, and the 
peptide sequence could be altered as a consequence of this. Three gaps in a row, or very 
near each other will not cause serious alteration in the peptide sequence.  
 
The C3:44F/R1 primers yielded a longer sequence than expected, and C3:48F/R1 primers 
yielded a shorter sequence than expected, these differences might be due to weak signals 
in the sequence, and the length of the sequence itself. The amount of DNA in the 
sequencing reaction is crucial, too little and the signals get to weak for a reliable reading, 
too much and the signals gets to strong for a reliable reading, they disturb the sequence.  
This have probably been the reason for the bad sequences and the differences in expected 
size and obtained size. Most differences were due to terminal gaps, which could be in 
both ends of both strands, and therefore the sequence could be shortened in both 
directions and maybe in the middle if both sequences had bad overlapping ends. In some 
sequences there was not even possible to read the primer sequences, in some cases there 




There might be other reasons for bad sequences. Contamination of the template with for 
example other DNA extracts, an extra primer and proteins will affect the out coming 
sequence. Unspecific primers can also cause problems because they bind to different 
places in the genome, and not necessarily within the region to be sequenced, and leads to 
a disturbing background that can be difficult to segregate from the sequence [The DNA 
Sequencing Core Facility] 
 
Cloning into pDEST17 
Pili C3:48 insert was not confirmed in the pDEST17 vector, but the transformation 
yielded some colonies on selective plates, so the transformation was successful, and the 
orientation of the insert was confirmed in pENTR, the orientation should not shift when 
the insert is recombined between the to vectors, but a new check of orientation should 
have been done just in case the insert orientation shifted during the recombination.  
 
There might have been some problem with the LR-recombination reaction setup for pili 
C3:48, the donor:receptor vector ratio might have been wrong, but the amount 
recommended in the protocol was used, which indicate that it could be an idea to 
optimize the reaction, or that the NanoDrop results differed from the actual concentration. 
 
Pili 1:44 was recombined, transformed and expressed using the same protocol used for 
pili C3:48, the LR-recombination and transformation of the two genes were done at the 




The protein expression showed that pili 1:44 protein was expressed in amounts suitable 
for purification, it created distinctive bands in the chemiluminicent detection, it was a bit 
smaller than expected and it was water insoluble; this might be because of the 
hydrophobic domain and the following charged tail, which groups the pili proteins with 
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the CWAPs. The hydrophobic domain and the charged tail anchor the pili to the cell wall 
[Fischetti et al. 1990, Boekhorst 2005] and this anchoring to the wall can have been too 
strong and made it difficult not to pellet the pili protein with the water insoluble proteins. 
A relatively easy way to check this is to boil the cell wall fraction and run a SDS PAGE 
and look for a several distinctive bands were the difference in size is the same as the size 
of one subunit [Scott & Zähner 2006]. 
 
A way of getting a water soluble protein could be to reduce the coding region to be 
expressed, so that the LPXTG motif is excluded, in this way the hydrophobic domain and 
the charged tail would not be expressed. A reasonable place to end the region to be 
expressed would be after the T in the LPXTG motif, since this is were sortase works to 
remove the hydrophobic domain and charged tail, and link the subunits to each other. 
 
To avoid cloning and expression, a defined region of the putative pili protein could be 
synthesized in vitro. Hendrickx et al [2008] used a 15 amino acid long peptide sequence 
to produce antibodies for electron microscopy, but they did not achieve successful results 
for C3:44 using this method. 
 
Another way of making antibodies that will recognise the protein is to make a fusion 
protein that is soluble and purify it. A fusion protein is the product of two different genes 
that are ligated together [Nelson & Cox 2005]. 
 
The protein could be in the water insoluble fraction because of failed cell lysis. Using 
another lysis buffer, or using glass beads or sonication together with lysis buffer could 
confirm an eventual lack of lysis and lyse the cells. 
 
The overall goal is to purify the protein and produce antibodies for immunogold labelling 
and electron microscopy, where C3:48, from PGC3, would appear as a flexible structure 
over 1µm at the poles of the cells, and uniformly distributed over the surface of single 




Further approaches  
The main work for this thesis had to be terminated when the protein turned out to be in 
the water insoluble fraction after the pilot expression and cell lysis. To overcome this 
problem other lysis methods can be tried out, the LPXTG can be left out of the region to 
be expressed as discussed above, a fusion protein can be made or cloning of a specific 
peptide sequence can be tried.  When the protein is water soluble it can be purified, there 
are many kits that purify proteins with different tags, and the most used is the small his-
tag. The purified protein is used to make antibodies for screening for the protein in 
electron microscope.  
 
When preparing the cells for transmission electron microscopy it is important to be aware 
of the possibilities for artefacts in the final result, every step in the preparation can cause 
an artefact in the final result [Bozzola and Russel 1999].   
 
When immunolabeling is preformed for electron microscopy, tagged secondary 
antibodies are often used in addition to the primary antibodies. Reasons for this is that the 
use of primary antibodies can cause problems for the antibodies ability to bind to the 
antigen because of the tag that have to be used for detection. Another problem with using 
primary antibody is the difficulty of obtaining a conjugation between the tag and 
antibody, and it is often inefficient.  
 
The secondary antibodies do not cause these problems, and they enhance the signal 
because more than one molecule can bind to the antigen (primary antibody), so more tags 
are connected to the antigens in the cells [Bozzola and Russel 1999]. These things have to 
be in mind when deciding if only primary antibody should be used, or if a secondary 
antibody should be used in addition to the primary. The concentration of antibodies has to 
be adjusted, this easiest done by checking a series of preparates with different antibody 
concentrations in the microscope. 
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When pili is confirmed there could be put some effort in looking for the other pili 
proteins coded for in the identified gene clusters, PGC1, PGC2, PGC 3 and PGC4, check 
for their localization in the cell, or on the cell, and screen for the presence of these genes. 
There could also be put some effort in detection of the sortase that has been identified. 
 
Prevalence of Pili Genes 
The overall results indicates that pili are a virulence factor, due to the correlation of pili 
1:44 to the hospital, and the correlation of pili 1:48 to the isolates from blood, and the 
isolates with vancomycin resistance. Both structures showed correlation to factors outside 
the hospital, and humans; pili 1:44 had a correlation to samples from other sources than 
faeces, and pili 1:48 showed a correlation to animals, this indicates that pili is important 
also outside the hospital. 
 
Pili 1:44 Prevalence 
The prevalence of pili genes showed that pili 1:44 is correlated to the hospital 
environment, but not to clinical isolates. The correlation was in hospital survey isolates 
and in hospital outbreak isolates, suggesting that pili 1:44 is important for E. faecium 
survival in the hospital environment, and for causing infections when under the right 
circumstances. 
 
The correlation of E. faecium to hospital outbreaks could also indicate that E. faecium is 
easily transferred between infected patients; this transformation can be indirect via 
medical devices, the clothes and hands of health care personnel or by surfaces that is 
often in contact with other persons, both health care personnel and other patients. The 
transfer between patients can also be more direct, like direct contact between the patients. 
 
The correlation between 1:44 and the hospital survey supports the idea of E. faecium 
being able to survive in the hospital environment, and that the transfer via indirect routes 
is possible, and even probable. The expression of pili in the hospital environment can be 
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an advantage in maintaining the population, in the acquisition of new mechanisms that 
can make them even more potent to humans. Which support the idea of pili 1:44 being 
important for the survival in the hospital environment. 
 
Pili 1:48 prevalence 
The expression of pili 1:48 showed a correlation to blood, vancomycin resistance and 
animals. Pili 1:48 is thought to be a subunit of the pili C3:48 structure, which has been 
shown to be a long flexible structure [Hendrickx et al.. 2008]. 
 
The expression of pili in E. faecium isolates from blood indicates that this long flexible 
structure is an advantage in this environment. The pili can help E. faecium to attach to 
blood cells or to the blood vessel it-self, and pili could help the bacteria to translocate 
from the blood vessel into new sites in the body and cause infection there.  
 
The p-values also indicate that there are correlations between pili 1:48 and vancomycin 
resistance, preferably vanA. This could be a problem if E. faecium with pili and 
vancomycin resistance is the cause of bacteriemia, or other blood borne diseases. The 
enterococcal infection would be harder to treat because of the vancomycin resistance, and 
the pili would make it easier for the enterococci to adhere to host cells, or translocate to 
other sites. 
 
The correlation between pili and animals could mean that the structure is an advantage in 
other environments than the hospital. The isolates from animals were all, but two, from 
community survey, and there is no information about E. faecium in clinical isolates from 
animals, and therefore nothing can be said about animal invasive E. faecium, and no 
conclusion about the function of pili in animal pathogens. The material does not include 
the information about what sort of animal origin the isolates come from, so the 
correlation might be false.  
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Differences Between 1:44 and 1:48 
The pili 1:44 is more spread than pili1:48, with 67 (92%) positives out of total 73 
positives, with 36 (49%) isolates positive for only 1:44. The 1:48 has 37 (51%) positive 
isolates out of the 73 positive isolates, and only 6 (8%) isolates with only pili 1:48. These 
results indicate that pili 1:44 is more spread than pili 1:48; it might also indicate that pili 
1:44 is more useful for the enterococci than pili 1:48, or that pili 1:44 is an older gene 
cluster that have had more time to spread in different environments and over 
geographical areas. 
 
The environments the pili are expressed in have an influence of the rate the genes will 
spread, and how fast they will spread to other areas. Pili 1:44 is found in the hospital 
environment, this will make it easier to spread to other hospitals via persons travelling 
between hospitals, like for example patients that are transferred from one hospital to 
another.  
 
Pili 1:48 is expressed in the blood, and are dependent on contact between the bacteria in 
some waste from the body, and something in the environment that will transfer it to other 
areas. This “something” could for example be clothing, floor, health-care personnel or 
visitors, but these things would somehow have to get contamination and not wash it of or 
getting rid of it some other way before the bacteria are out in the environment. 
 
Hendrickx et al. 2008 showed that pili1:48 was more spread than pili 1:44, which is the 
opposite of the results in this thesis, this can reflect the isolates used for the screenings 
influenced the results. The isolates in this thesis was originally designed for another work 
[unpublished], and strains interesting for that work is included in this material. This 
material is unbalanced with regard to E. faecium isolates from animals.  
 
There is a correlation between the two genes, pili 1:44 and 1:48. This indicates that both 
pili could be physically linked by being located near each other on the same genetic 
element, or that they are exposed to the same selective pressure. If they had been located 
on the same genetic element, all isolates would probably have tested the same for both 
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pili 1:44 and pili 1:48, this is not the case, so the genes must be exposed to the same 
selective pressure, even though they are expressed in complete different environments.  
 
The reason for their correlation could be as simple as pili 1:44 provides an advantage 
between hosts to infect, and that pili 1:48 is not needed in this environment. When E. 
faecium infect the host another type of pili is needed, and then 1:48 is expressed and not 
1:44. This would make it an advantage for the E. faecium to have both pili, and they are 
selected together by the ability to survive in both the hospital environment and in blood. 
 
The difference in distribution indicates that the pili have different functions for the 
survival. Or it could indicate that they are expressed under different conditions. The 
hospital environment is probably a cold environment compared to the blood, which 
would indicate that pili 1:44 is expressed under colder conditions than 1:48. According to 
Hendrickx et al [2008] pili 1:48 will not be completely expressed at 21ºC (room 
temperature), but monomeric forms of C3:48 was observed. When the cells were grown 
at 37ºC the C3:48 was expressed as a fully polymerised pili structure. This support the 
results of this thesis, that indicate that the two pili genes are expressed at different 
temperatures, because the environments they are correlated to have different 
temperatures, and that pili 1:48 is dependent on higher temperatures than 1:44, all though 
Hendrickx et al [2008] do not say anything about pili 1:44. 
 
Consequences of Pili 
The consequences of having pili associated with enterococci that are specialists in 
surviving in the hospital environment, like CC17, could be severe. The CC17 are already 
known for their antibiotic resistance and putative pathogenicity island containing the esp, 
acm and probably hylfm genes [Hendrickx et al. 2007], which cause problems in treating 
infections by these bacteria.  
 
Pili are thought to be an advantage for bacterial adherence to host tissue and some pili 
structures are involved in biofilm formation (ebp) [Singh et al 2006], this could make it 
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easier for the enterococci to infect a host, and withstand treatment, due to the biofilms 
protection against antibiotic effects [Merode et al. 2006]. 
 
Pili is also thought to be involved in cell-cell communication, and plasmids and other 
genetic elements can be transferred to other bacteria by conjugation, enterococci are 
known to transfer mobile genetic elements to other bacteria, this could be other 
enterococci species, Gram-positive bacteria or Gram-negative bacteria [Donelli et al. 
2004]. This transference to other species can be fatal if the receiver of the genetic 
elements is a human pathogenic bacterial strain like for example MRSA. 
 
Pili have been associated with biofilm production in E. faecium [Singh et al. 2006], and 
this in connection with vancomycin resistance could cause a problem in treating E. 
faecium infections, and the combination could be an extra advantage for survival, both 
in/on the host and in the surroundings. The results from this work do not indicate this to 
be a problem, yet. The gene correlated with vancomycin resistance was not correlated 
with the surrounding environment, and the gene that had a significant correlation to the 
hospital environment did not show any correlation to vancomycin resistance. 
 
The antibiotic pressure in the hospital setting is high, and screenings for resistance to 
other antibiotics in the isolates could reveal more about their adaptation to this 
environment, and indicate if it is a hospital subpopulation in development or if it is an 







1. To design PCR tools for amplification of putative pili coding sequences from E. 
faecium. 
 
This was successfully done. The PCR programs obtained was used for sequencing 
and cloning. Not all primers were optimalized, only the primers used for cloning 
(C3:44R1 and C3:48R1), pili 3:48 F and pili 3:48R, these were optimalized because 
of problems with unspecific binding in the negative control, and to some extent in the 
positive control. 
 
2. To perform TOPO-cloning of amplicons into pENTR-vector by directional insertion, 
and to recombine the inserts into pDEST17 for expression. 
 
Both genes to be cloned, C3:44 and C3:48, were successfully cloned into the pENTR 
vector and transformed into TOP10 chemically competent E. coli cells. Plasmids 
from clones with confirmed insert was purified from overnight cultures of these cells, 
the overnight cultures was also used to make a freeze culture for long time storage. 
 
Only C3:44 was successfully recombined into pDEST17, and transformed into DH5α 
chemically competent cells for maintaining the pDEST17 vector with the confirmed 
inserts. C3:48 formed colonies after the recombination and transformation, but no 
inserts were confirmed, and the experiments involving C3:48 stopped at this point. 
 
3. To purify the putative pili proteins by affinity chromatography and inject rabbits for 
production of polyclonal antibodies. 
 
Before the expression, plasmids had to be isolated from the DH5α cells and 
transformed into BL21-AI cells containing the T7 promoter. The expression of C3:44 
pili protein showed that the protein is water insoluble, and the work for detection of 
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pili in E. faecium was terminated. The reason for the protein being water insoluble are 
probably the hydrophobic domain, which LPXTG is a part of, and the charged tail 
that is used to keep the protein in the cell wall long enough for sortase to bind and 
link the protein to another pili subunit. 
 
This problem can be avoided by cutting of the G in the LPXTG motif, or cutting the 
whole motif of. Other ways of avoiding this problem is to clone a part of the gene to 
get a peptide sequence, or fuse the protein to make it soluble. The protein has to be 
soluble for purification. 
 
4. To detect pili by electron microscopy with immunogold labeling. 
 
Because of the protein being water insoluble it was not purified and it was not 
possible to produce antibodies, and the electron microscopy work for this thesis was 
not accomplished.  
 
5. To design PCR tools for screening of pili genes in a collection of E. faecium isolates. 
 
PCR tools for screening of the pili genes were successfully done. Before screening 
the PCR programs was optimalized, due to problems with unspecific primer binding 
to the negative control, and to some extent in the isolated E. faecalis DNA.  
 
The results showed that pili 1:44 is correlated to isolates from hospital survey and 
hospital outbreak. 1:44 was also shown to correlate to isolates taken from animals, 
from sources other than faeces. 
 
Pili 1:48 was shown to correlate to isolates from blood and animal faeces, it was also 
shown to be a correlation between pili 1:48 and vancomycin resistance. 
 
Pili 1:44 and pili 1:48 are thought to be correlated to each other; this is based on the 
results in this thesis. The correlation is probably due to the same selective pressure. 
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The results also indicate that the two genes have different roles in E. faecium, due to 
the correlation to different environments. Pili 1:44 is thought to be expressed under 
room temperature, this is assumption is not tested, but based on the correlation to 
isolates from hospital survey. Pili 1:48 has been shown to down regulate the 
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Appendix A: DNA sequences 
Pili C3:44/ Contig 651 alignment with primers. Primers written in blue were used for 
cloning, while primers written in green were used for sequencing, the red markings 
indicates the differences between contig 651 and the obtained C3:48 sequence. The M13 
primers are not included because they were located in the vector. For more information 
about the primers see tables 5 and 12. 
 
     Pili C3:44F  
C3:44  1    CACCGGAATG AGTGTACTGT TACTCGTTAC TGCGGGAATA GGGATTTTCG GGAACGGAAA ACTAGTCAAA   
651    1    CACGGGAATG AGTGTACTGT TACTCGTTAC TGCGGGAATA GGGATTTTCG GGAACGGAAA ACTAGTCAAA   
 
C3:44  71   GCCGAAGAAG TCGCACAAAA ACCAAGTGAA GTGACGATTA CATTACACAA AAAAGGTTTC TCATCTGTTC   
651    71   GCCGAAGAAG TCGCACAAAA ACCAAGTGAA GTGACGATTA CATTACACAA AAAAGGTTTC TCATCTGTTC   
 
C3:44  141  CGGAAGAACG ACCGAATAGC GGATTGGTTT CTACGGATTT TGGTGAAGAA AATATTCCAG GAGTCGATTT   
651    141  CGGAAGAACG ACCGAATAGC GGATTGGTTT CTACGGATTT TGGTGAAGAA AATATTCCAG GAGTCGATTT   
 
C3:44  211  TGATTTGTTT GACGTAACGG AAGTATATTA CGATTTGATT CGAGATAATC CTTTAACACC GGAACGAGAA   
651    211  TGATTTGTTT GACGTAACGG AAGTATATTA CGATTTGATT CGAGATAATC CTTTAACACC GGAACGAGAA   
 
C3:44  281  GACGGTCTTA ATTCTGCCGA AGCGATTGAA TGGATTCAAA AACGGCACAC AGAAAGTTGG TTTTTAAAAT   
651    281  GACGGTCTTA ATTCTGCCGA AGCGATTGAA TGGATTCAAA AACGGCACAC AGAAAGTTGG TTTTTAAAAT   
 
C3:44  351  ATCGACTGAC AAGTATTGAC AAACAAACAA CGAATGAAGC TGGAGAAGCG GTATTCTCTA CCGTCCAAGT   
651    351  ATCGACTGAC AAGTATTGAC AAACAAACAA CGAATGAAGC TGGAGAAGCG GTATTCTCTA CCGTCCAAGT   
 
C3:44  421  GACGGAAGAA GCACCTTCTT CTAGAGATAA AGTCTATCTT TTCTTAGAAA CTTATTCGCC AGCTCATATT   
651    421  GACGGAAGAA GCACCTTCTT CTAGAGATAA AGTCTATCTT TTCTTAGAAA CTTATTCGCC AGCTCATATT   
        Pili 3:44FM  
C3:44  491  TCCAGAATCG CGTCTCCAAT GGTTGTTATG ATGCCAGTGA TGATGCCTGA TATGGTGGAT GGCGTGTGGG   
651    491  TCCAGAATCG CGTCTCCAAT GGTTGTTATG ATGCCAGTGA TGATGCCTGA TATGGTGGAT GGCGTGTGGG   
      Pili 3:44 RL 
C3:44  561  ATGGTTCTAC ATGGAAAGAC ACATACAATA CAGATGTGCA TTTGTATCCG AAAAACGAAA TCAGAGAAGC   
651    561  ATGGTTCTAC ATGGAAAGAC ACATACAATA CAGATGTGCA TTTGTATCCG AAAAACGAAA TCAGAGAAGC   
 
C3:44  631  AGATAAACAG ATGAATGTAG AGGAAAGCGA CCTTAGACAA GTAACGATTA TTAATGAAGC TGGAGAACAA   
651    631  AGATAAACAG ATGAATGTAG AGGAAAGCGA CCTTAGACAA GTAACGATTA TTAATGAAGC TGGAGAACAA   
 
C3:44  701  GAAACGATTT CTTATATTGA TCTAGAAAGA GGAAAAACGG CTTCTTACAC GATCACAGCA CCTATTCCTT   
651    701  GAAACGATTT CTTATATTGA TCTAGAAAGA GGAAAAACGG CTTCTTACAC GATCACAGCA CCTATTCCTT   
 
C3:44  771  ATTTCATCGA TTCTGTCCTT GAAAACGGAA GCGCTGTTAT CAAAAATTAC AAAATCACAG ATACGCCTAC   
651    771  ATTTCATCGA TTCTGTCCTT GAAAACGGAA GCGCTGTTAT CAAAAATTAC AAAATCACAG ATACGCCTAC   
 
C3:44  841  AGTTGGTCTA ACTTATTATG ATCAGGAAAT AGAAGTGCGA GCCGGCGAGA CGATTTTAAC AAAAGGACAA   
651    841  AGTTGGTCTA ACTTATTATG ATCAGGAAAT AGAAGTGCGA GCCGGCGAGA CGATTTTAAC AAAAGGACAA   
 
C3:44  911  GATTATATAG TAGAAGTAGT AAGCAACGGG TTTGTCGTGA CGATTTTGAC AGAAGAAAAT GGAGTAGCCA   
651    911  GATTATATAG TAGAAGTAGT AAGCAACGGG TTTGTCGTGA CGATTTTGAC AGAAGAAAAT GGAGTAGCCA   
 
C3:44  981  AAGTAGATAC TTTAGGTAGA TTAGCAGATG CACGTGGAGG AGATTTAACG ATCACGTATA ATTTGAAGGT   
651    981  AAGTAGATAC TTTAGGTAGA TTAGCAGATG CACGTGGAGG AGATTTAACG ATCACGTATA ATTTGAAGGT   
 
C3:44  1051 TTCCACAGAA CTAGAAGCGG ATGATTTCCA TAACAACACA GCGGTTATTG AAATCGGACG AAATGATGAA   
651    1051 TTCCACAGAA CTAGAAGCGG ATGATTTCCA TAACAACACA GCGGTTATTG AAATCGGACG AAATGATGAA   
         Pili 3:44FR  
C3:44  1121 TTTGATTATG AAGAAGGAGT AGAGCCGCCA GAGAAAGTCA CAACAGGTGG AAGAAAGTTT GAAAAATATG  
 104
651    1121 TTTGATTATG AAGAAGGAGT AGAGCCGCCA GAGAAAGTCA CAACAGGTGG AAGAAAGTTT GAAAAATATG   
 
C3:44  1191 ATGCATCAAG CAGTGAATTG CTTAAAGATG CAAGATTCGA ATTGTGGAAT GAAGACCGTT CTGAATACGC   
651    1191 ATGCATCAAG CAGTGAATTG CTTAAAGATG CAAGATTCGA ATTGTGGAAT GAAGACCGTT CTGAATACGC   
        Pili 3:44FM 
C3:44  1261 AATATTTTAT AAAGGGGAGT CGCCTTTAGC TGTTTATGAA TCAGGAGCAG ATAGAATTGA GTGGGCAACA   
651    1261 AATATTTTAT AAAGGGGAGT CGCCTTTAGC TGTTTATGAA TCAGGAGCAG ATAGAATTGA GTGGGCAACA   
 
C3:44  1331 AGCGGACAAG CAACAGAATT TGTCGCAGAT GGAAATGGAT ACTTTGAGGT TCAAGGGTTA GATTATGGAA   
651    1331 AGCGGACAAG CAACAGAATT TGTCGCAGAT GGAAATGGAT ACTTTGAGGT TCAAGGGTTA GATTATGGAA   
 
C3:44  1401 CCTATCAAAT GAAAGAGACC ATGGCGCCAG AAGGTTATGT ACTTCCAACA GGTGAGGCAG CCTTTACTGA   
651    1401 CCTATCAAAT GAAAGAGACC ATGGCGCCAG AAGGTTATGT ACTTCCAACA GGTGAGGCAG CCTTTACTGA   
 
C3:44  1471 ATTTATCATC TCTTATGGAA GCTATAATGA AGAAATTCAG ATCGTAGGAG TAGAAAATCC AGGGCCAGAA   
651    1471 ATTTATCATC TCTTATGGAA GCTATAATGA AGAAATTCAG ATCGTAGGAG TAGAAAATCC AGGGCCAGAA   
 
C3:44  1541 AGAGTACCGA ATATGAAACG CGGGTCACTT CCTGCTACTG GTGGGAACGG GCTCTTGGCA TTCTTACTAA   
651    1541 AGAGTACCGA ATATGAAACG CGGGTCACTT CCTGCTACTG GTGGGAACGG GCTCTTGGCA TTCTTACTAA   
          Pili C3:44 R1 
C3:44  1611 TCGGAATAAG TTTGATGATT GGAGCGTACA GCTGGTACCG TAAATCTAAA ATGAAGTCTG AAGTATAA  
651    1611 TCGGAATAAG TTTGATGATT GGAGCGTACA GCTGGTACCG TAAATCTAAA ATGAAGTCTG AAGTATAA  
 





Pili C3:48/ Contig 657 alignment with primers. Primers written in blue were used for 
cloning, while primers written in green were used for sequencing, the red markings 
indicates the differences between contig 657 and the obtained C3:48 sequence. The M13 
primers are not included because they were located in the vector. For more information 
about the primers see tables 5 and 12. 
         Pili C3:48 F  
C3 48  1    CACCATGTTA GGAGTCCTTT TCCTTATTT T ACCATTACTC ACAAACAGCT TCGGCGCAAA AAAAGTGTTT   
657    1    CGTTATGTTA GGAGTCCTTT TCCTTATTT T ACCATTACTC ACAAACAGCT TCGGCGCAAA AAAAGTGTTT   
 
C3 48  71   GCAGAGGAGA CAGCAGCTCA AGTCATCCTT CATAAAAAGA AAATGACTGA TTTACCCGAT CCTTTAATCC   
657    71   GCAGAGGAGA CAGCAGCTCA AGTCATCCTT CATAAAAAGA AAATGACTGA TTTACCCGAT CCTTTAATCC   
 
C3 48  141  AAAACAGCGG GAAAGAAATG AGCGAATTCG ATCAATACCA AGGATTAGCC GATATTTCAT TTTCAGTTTA   
657    141  AAAACAGCGG GAAAGAAATG AGCGAATTCG ATCAATACCA AGGATTAGCC GATATTTCAT TTTCAGTTTA   
 
C3 48  211  TAACGTCACT CAAGAATTTT ATGCGCAACG AGATAAAGGA GCGTCCGTGG ATGCAGCAAA ACAAGCAGTC   
657    211  TAACGTCACT CAAGAATTTT ATGCGCAACG AGATAAAGGA GCGTCCGTGG ATGCAGCAAA ACAAGCAGTC   
 
C3 48  281  CAGTCTTTGA CTCCTGGTAC ACCAGTTGCT TCAGGAACGA CAGATGCTGA TGGAAATGTC ACTTTATCTT   
657    281  CAGTCTTTGA CTCCTGGTAC ACCAGTTGCT TCAGGAACGA CAGATGCTGA TGGAAATGTC ACTTTATCTT   
              Pili 3:48FM  
C3 48  351  TACCTAAAAA ACAAAATGGG AAAGATGCAG TCTACACGAT CAAAGAAGAA CCAAAAGACG GAGTGTCAGC   
657    351  TACCTAAAAA ACAAAATGGG AAAGATGCAG TCTACACGAT CAAAGAAGAA CCAAAAGACG GAGTGTCAGC   
 
C3 48  421  TGCCGCAAAC ATGGTTTTAG CTTTCCCTGT ATATGAGATG ATCAAACAAG CAGATGGCTC TTATAAATAC   
657    421  TGCCGCAAAC ATGGTTTTAG CTTTCCCTGT ATATGAGATG ATCAAACAAG CAGATGGCTC TTATAAATAC   
       Pili 3:48RL 
C3 48  491  GGGACAGAAG AACTAGATAC TATCCATCTC TACCCTAAAA ATACAGTCGG TAATGATGGA ACGTTGAAAG   
657    491  GGGACAGAAG AACTAGATAC TATCCATCTC TACCCTAAAA ATACAGTCGG TAATGATGGA ACGTTGAAAG   
 
C3 48  561  TTACAAAAAT CGGTACTGCC GAAAACGAAG CACTAAATGG AGCAGAATTT ATTATTTCTA AAGAAGAAGG   
657    561  TTACAAAAAT CGGTACTGCC GAAAACGAAG CACTAAATGG AGCAGAATTT ATTATTTCTA AAGAAGAAGG   
 
C3 48  631  AACACCAAGC GTCAAAAAAT ACATCCAAAG TGTCACAGAT GGATTGTACA CTTGGACAAC TGATCAAACC   
657    631  AACACCAAGC GTCAAAAAAT ACATCCAAAG TGTCACAGAT GGATTGTACA CTTGGACAAC TGATCAAACC   
 
C3 48  701  AAAGCCAAAC ATTTCATTAC TGGTCATTCT TATGACATCG GCAACAATGA CTTTGCCGAG GCATCTATTG   
657    701  AAAGCCAAAC ATTTCATTAC TGGTCATTCT TATGACATCG GCAACAATGA CTTTGCCGAG GCATCTATTG   
 
C3 48  771  AAAAAGGCCA GTTGATCGTT AATCATTTAG AAGTTGGAAA ATATAATTTA GAAGAAGTAA AAGCTCCTGA   
657    771  AAAAAGGCCA GTTGATCGTT AATCATTTAG AAGTTGGAAA ATATAATTTA GAAGAAGTAA AAGCTCCTGA   
             Pili 3:48FR  
C3 48  841  TAATGCGGAA ATGATTGAAA AGCAAACAAT CACGCCTTTT GAGATCCTGG CAAATAGCCA AACACCAGTA   
657    841  TAATGCGGAA ATGATTGAAA AGCAAACAAT CACGCCTTTT GAGATCCTGG CAAATAGCCA AACACCAGTA   
 
C3 48  911  GAAAAGACCA TCAAAAATGA TACGTCTAAA GTTGATAAAA CAACACCTCA ATTGAATGGA AAAGATGTCG   
657    911  GAAAAGACCA TCAAAAATGA TACGTCTAAA GTTGATAAAA CAACACCTCA ATTGAATGGA AAAGATGTCG   
 
C3 48  981  CAATCGGTGA AAAAATTCAA TATGAGATTT CTGTCAATAT CCCATTAGGT ATCGCTGATA AAGAAGGAAC   
657    981  CAATCGGTGA AAAAATTCAA TATGAGATTT CTGTCAATAT CCCATTAGGT ATCGCTGATA AAGAAGGAAC   
       Pili 3:48RM 
C3 48  1051 GCAAAACAAG TACACAACAT TCAAACTTA T CGATACTCAT GACGCTGCTT TAACATTTGA TAATGATTCT   
657    1051 GCAAAACAAG TACACAACAT TCAAACTTA T CGATACTCAT GACGCTGCTT TAACATTTGA TAATGATTCT   
 
C3 48  1121 TCAGGAACGT ATGCTTATGC CTTATATGAT GGAAATAAAG AAATCGACCC AGTAAATTAT TCTGTCACTG   
657    1121 TCAGGAACGT ATGCTTATGC CTTATATGAT GGAAATAAAG AAATCGACCC AGTAAATTAT TCTGTCACTG   
 
C3 48  1191 AGCAAACAGA CGGATTCACG GTTTCAGTTG ATCCGAATTA TATTCCTTCA TTAACTCCTG GCGGTACATT   
657    1191 AGCAAACAGA CGGATTCACG GTTTCAGTTG ATCCGAATTA TATTCCTTCA TTAACTCCTG GCGGTACATT   
          Pili 3:48F  
C3 48  1261 GAAATTCGTT TACTATATGC ATTTGAACGA AAAAGCAGAT CCAACCAAAG GATTTTCTAA CCAAGCAAAT   
657    1261 GAAATTCGTT TACTATATGC ATTTGAACGA AAAAGCAGAT CCAACCAAAG GATTTTCTAA CCAAGCAAAT   
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C3 48  1331 GTCGATAACG GGCATACAAA TGATCAAACA CCACCGTCAG TCGATGTCGT TACTGGGGGC AAACGATTTG   
657    1331 GTCGATAACG GGCATACAAA TGATCAAACA CCACCGTCAG TCGATGTCGT TACTGGGGGC AAACGATTTG   
 
C3 48  1401 TTAAAGTAGA TGGTGACGTT ACATCAGACC AAACACTTGC TGGAGCAGAA TTCGTCGTTC GTGATCAAGA   
657    1401 TTAAAGTAGA TGGTGACGTT ACATCAGACC AAACACTTGC TGGAGCAGAA TTCGTCGTTC GTGATCAAGA   
 
C3 48  1471 TAGTGACACA GCGAAATATT TATCGATCGA CCCATCCACA AAAGCCGTCA GCTGGGTATC GGCGAAAGAA   
657    1471 TAGTGACACA GCGAAATATT TATCGATCGA CCCATCCACA AAAGCCGTCA GCTGGGTATC GGCGAAAGAA   
              Pili 3:48R 
C3 48  1541 TCAGCAACGG TTTTTACAAC CACAAGTAAC GGTTTAATCG A TGTGACAGG TCTAAAATAT GGCACGTACT   
657    1541 TCAGCAACGG TTTTTACAAC CACAAGTAAC GGTTTAATCG A TGTGACAGG TCTAAAATAT GGCACGTACT   
 
C3 48  1611 ATCTGGAAGA AACGAAAGCG CCAGAAAAAT ATGTTCCATT AACAAACCGT GTAGCATTTA CTATCGATGA   
657    1611 ATCTGGAAGA AACGAAAGCG CCAGAAAAAT ATGTTCCATT AACAAACCGT GTAGCATTTA CTATCGATGA   
 
C3 48  1681 ACAATCTTAT GTAACAGCAG GACAGTTGAT TTCTCCTGAA AAAATACCAA ATAAACACAA AGGTACACTT   
657    1681 ACAATCTTAT GTAACAGCAG GACAGTTGAT TTCTCCTGAA AAAATACCAA ATAAACACAA AGGTACACTT   
 
C3 48  1751 CCTTCAACAG GCGGTAAGGG AATCTATGTG TATATCGGTG CAGGAGTAGT CCTTCTACTG ATTGCTGGAC   
657    1751 CCTTCAACAG GCGGTAAGGG AATCTATGTG TATATCGGTG CAGGAGTAGT CCTTCTACTG ATTGCTGGAC   
         Pili C3:48R1 
C3 48  1821 TGTACTTTGC TAGACGCAAG CACAGTCAGA TTTAG  
657    1821 TGTACTTTGC TAGACGCAAG CACAGTCAGA TTTAG  
 
This sequence will give a gene product with the approximate size 173998,33 Daltons 
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Appendix B: Estimation of P-Values 
Table B1- Calculation of χ and reading of p-value for screening 1:44 
Type Σ=((O-E)-0,5)2/E p 
Human  1,067 0,1 
Community Survey 0,281 0,5 
Hospital Survey 10,685 0,005 
Outbreak 3,067 0,1 
Hospital outbreak 3,984 0,05 
Clinical 0,377 0,5 
Other 0,368 0,5 
Faeces 1,659 0,1 
Blood 1,814 0,1 
Urine 0,559 0,5 
Other 0,534 0,5 
From two sites 2,046 0,1 
VanA and VanB 0,191 0,9 
   VanA  0,063 0,9 
   VanB 0,562 0,5 
USA 0,350 0,5 
Europa 0,562 0,5 
   Scandinavia 1,448 0,1 
      Norway 0,166 0,9 
Other 2,207 0,1 
Community survey 7,199 0,01 
Other  - - 
Faeces 2,109 0,1 
Other 7,604 0,005 
VanA and B 0,493 0,5 
   VanA  0,493 0,5 
   VanB  - - 
Animal pili 0,571 0,5- 
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Table B2- Calculation of χ and reading of p-value for screening 1:48. 
Type Σ=((O-E)-0,5)2/E p 
Human  1,942 0,5 
Community Survey 0,361 0,5 
Hospital Survey 0,877 0,5 
Outbreak 0,767 0,5 
Hospital outbreak 0,160 0,5 
Clinical 0,342 0,5 
Other 0,523 0,5 
Faeces 1,970 0,1 
Blood 5,844 0,025 
Urine 0,238 0,5 
Other 0,321 0,5 
From to sites 2,937 0,1 
VanA and VanB 6,248 0,01 
   VanA  8,062 0,005 
   VanB 0,554 0,5 
USA 0,275 0,5 
Europa 0,554 0,5 
   Scandinavia 0,101 0,9 
      Norway 0,676 0,5 
Other 2,056 0,1 
Animals  4,740 0,025 
Community survey 2,274 0,1 
Other 2,274 0,1 
Faeces 2,274 0,1 
Other 2,274 0,1 
VanA and B 0,694 0,5 
   VanA  0,694 0,5 







Figure B1- Table over critical values for χ2 distribution. 
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